ROC

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period endedJune 30, ~~2022~~2023


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 021-340690

TerrAscend Corp.

(Exact Name of Registrant as Specified in its Charter)


Ontario	N/A
( State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
~~3610 Mavis Road~~77 City Centre Drive Suite 501 - East Tower Mississauga, Ontario	~~L5C 1W2~~L5B 1M5
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (~~855~~717) ~~837-7295~~610-4165

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

~~N/A~~None

N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☐
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ ~~No ☐~~

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ ~~No ☐~~

As of August 9, ~~2022,~~2023, the registrant had ~~252,907,618~~286,961,175 ~~shares of~~ common ~~stock,~~shares, $0.01 par value per share, outstanding.

Table of Contents


		Page

PART I.	FINANCIAL INFORMATION	1

Item 1.	Financial Statements (Unaudited)	1
	Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022	1
	Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months and six months ended June 30, 2023 and 2022	2
	Unaudited Interim Condensed Consolidated Statements of ~~Operations~~Changes in Shareholders' Equity for the three months and ~~Comprehensive Loss~~six months ended June 30, 2023 and 2022	2
	Unaudited Interim Condensed Consolidated Statements of Cash Flows for the three months and six months ended June 30, 2023 and 2022	5
	Notes to Unaudited Interim Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2427
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	3441
Item 4.	Controls and Procedures	3541

PART II.	OTHER INFORMATION	3542

Item 1.	Legal Proceedings	3542
Item 1A.	Risk Factors	3542
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3542
Item 3.	Defaults Upon Senior Securities	42
Item 4.	Mine Safety Disclosures	42
Item 5.	Other Information	42
Item 6.	Exhibits	3642
Signatures		3945

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains statements that TerrAscend Corp. ~~(“TerrAscend”~~("TerrAscend" or the ~~“Company”~~"Company") believes are, or may be considered to be, “forward-looking ~~statements.”~~statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q regarding the prospects of ~~the Company’s~~TerrAscend’s industry or ~~the Company’s~~TerrAscend’s prospects, plans, financial position or business strategy may constitute forward-looking statements. Such statements can be identified by the use of forward-looking terminology such as "can", “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Forward-looking statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Forward-looking statements in this Quarterly Report on Form 10-Q include, but are not limited to, statements with respect to:


•	~~the performance of the Company’s business and operations;~~

•

the performance of TerrAscend’s business and operations;

•

TerrAscend’s expectations regarding revenues, expenses and anticipated cash needs;

•

TerrAscend's joint venture interests, including, as applicable, required regulatory approvals and licensing, anticipated costs and timing, expected impact thereof, and the ability to enter into future joint ventures;

•

TerrAscend's ability to complete future strategic alliances and the expected impact thereof;

•

TerrAscend's ability to source investment opportunities and complete future acquisitions, including in respect of entities in the United States, the ability to finance such acquisitions, and the expected impact thereof, including potential issuances of TerrAscend's common shares;

•

TerrAscend's ability to continue as a going concern;

•

TerrAscend may be subject to certain restrictions of the Toronto Stock Exchange, which may constrain our ability to expand our business in the United States;

•

certain restrictions or limitations on TerrAscend's ability to distribute and expend capital due to the Company's corporate restructure;

•

the expected growth in the number of customers and patients using TerrAscend's recreational and medical cannabis, respectively;

•

the expected growth in TerrAscend's cultivation and production capacities;

•

expectations with respect to future production costs;

•

the expected methods to be used by TerrAscend to distribute cannabis;

•

the expected growth in the TerrAscend's number of dispensaries;

•

the competitive conditions of the industry;

•

federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the U.S. relating to cannabis operations in the U.S.;

•

the legalization of the use of cannabis for medical and/or recreational use in the U.S. and the related timing and impact thereof;

•

laws and regulations and any amendments thereto applicable to the business and the impact thereof;

•

the possibility of actions by individuals, or U.S. federal government enforcement actions, against TerrAscend and the potential impact on TerrAscend;

•

the competitive advantages and business strategies of TerrAscend;

•

the grant, renewal and impact of any license or supplemental license to conduct activities with or without cannabis or any amendments thereof;

•

the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis;

•

TerrAscend's future product offerings;

•

the anticipated future gross margins of TerrAscend's operations;


•	~~the Company’s expectations regarding revenues, expenses and anticipated cash needs;~~


•	~~the competitive conditions of the industry;~~

•

TerrAscend’s ability to source and operate facilities in the United States;

•

TerrAscend’s ability to integrate and operate the assets acquired from previous acquisitions;

•

Michigan's plans to continue building a diverse portfolio of branded cannabis assets and business arrangements through investments, strategic business relationships and the pursuit of licenses in attractive retail locations in Michigan;

•

the growth of the Michigan wholesale and retail business;

•

the potential impact of a public health emergency or pandemic, such as the COVID-19 pandemic;

•

TerrAscend's ability to protect its intellectual property;

•

the possibility that TerrAscend's products may be subject to product recalls and returns; and

•

other risks and uncertainties, including those listed under the section titled "Risk Factors" in this Quarterly Report


•	~~federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the US relating to cannabis operations in the US;~~


•	~~the legalization of the use of cannabis for medical and/or recreational use in the US and the related timing and impact thereof;~~


•	~~laws and regulations and any amendments thereto applicable to the business and the impact thereof;~~


•	~~the competitive advantages and business strategies of the Company;~~


•	~~the Company’s ability to source and operate facilities in the US;~~


•	the Company’s ability to integrate and operate the assets acquired from Arise Bioscience Inc. (“Arise”), the Apothecarium Dispensaries (“The Apothecarium”), Valhalla Confections (“Valhalla”), Ilera Healthcare (“Ilera”), State Flower or ABI SF LLC (“State Flower”), HMS Health, LLC, KCR Holdings LLC, and Gage;
•	~~any benefits expected from the Gage Acquisition; and~~


•	Gage’s plans to continue building a diverse portfolio of branded cannabis assets and business arrangements through investments, strategic business relationships and the pursuit of licenses in attractive retail locations in Michigan.

Certain of the forward-looking statements contained herein concerning the cannabis industry and the general expectations of ~~the Company~~TerrAscend concerning the cannabis industry are based on estimates prepared by ~~the Company~~TerrAscend using data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the cannabis industry. Such data is inherently imprecise. The cannabis industry involves risks and uncertainties that are subject to change based on various factors, which factors are described further below.

With respect to the forward-looking statements contained in this Quarterly Report on Form 10-Q, ~~the Company~~TerrAscend has made assumptions regarding, among other things: (i) its ability to generate cash flows from operations and obtain necessary financing on acceptable terms; (ii) general economic, financial market, regulatory and political conditions in which ~~the Company~~TerrAscend operates; (iii) the output from ~~the Company’s~~TerrAscend’s operations; (iv) consumer interest in ~~the Company’s~~TerrAscend’s products; (v) competition; (vi) anticipated and unanticipated costs; (vii) government regulation of ~~the Company’s~~TerrAscend’s activities and products and in the areas of taxation and environmental protection; (viii) the timely receipt of any required regulatory approvals; (ix) ~~the Company’s~~TerrAscend’s ability to obtain qualified staff, equipment and services in a timely and cost efficient manner; (x) ~~the Company’s~~TerrAscend’s ability to conduct operations in a safe, efficient and effective manner; and (xi) the Company’s construction plans and timeframe for completion of such plans.

Readers are cautioned that the above list of cautionary statements is not exhaustive. Known and unknown risks, many of which are beyond the control of ~~the Company,~~TerrAscend, could cause actual results to differ materially from the forward-looking statements in this Quarterly Report on Form 10-Q. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States ("U.S.") relating to cannabis operations in the ~~United States;~~U.S.; and those discussed under Item 1A – “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the “SEC”) on March 16, 2023 and this Quarterly Report on Form 10-Q. The purpose of forward-looking statements is to provide the reader with a description of management’s expectations, and such forward-looking statements may not be appropriate for any other purpose. You should not place undue reliance

on forward-looking statements contained in this Quarterly Report on Form 10-Q. ~~The Company~~TerrAscend can give no assurance that such expectations will prove to have been correct. Forward-looking statements contained herein are made as of the date of this Quarterly Report on Form 10-Q and are based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking statements are made. ~~The Company~~TerrAscend undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by applicable law.

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

TerrAscend Corp.

Unaudited Interim Condensed Consolidated Balance Sheets

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)


	At			At			At			At
	June 30, 2022			December 31, 2021			June 30, 2023			December 31, 2022
Assets
Current Assets
Cash and cash equivalents	$	48,426		$	79,642		$	28,915		$	26,158
Restricted cash		605			—			3,106			605
Accounts receivable, net		22,189			14,920			9,478			22,443
Investments		4,072			—			1,932			3,595
Inventory		54,371			42,323			54,015			46,335
Prepaid Expenses and other current assets		7,655			6,336
Assets held for sale								—			17,349
Prepaid expenses and other current assets								8,674			4,937
Current assets from discontinued operations								509			571
		137,318			143,221			106,629			121,993
Non-Current Assets
Restricted cash - Non-current								2,500			—
Property and equipment, net		238,797			140,762			208,995			215,812
Deposits		4,698			—			406			837
Operating lease right of use assets		30,570			29,561			32,824			29,451
Intangible assets, net		351,638			168,984			269,594			239,704
Goodwill		240,598			90,326			99,952			90,328
Indemnification asset		-			3,969
Other non-current assets		4,998			5,111			848			3,462
		871,299			438,713			615,119			579,594
Total Assets	$	1,008,617		$	581,934		$	721,748		$	701,587

Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable and accrued liabilities	$	57,535		$	30,340		$	50,841		$	44,286
Deferred revenue		2,404			1,071			3,092			2,935
Loans payable, current		58,856			8,837			23,928			48,335
Contingent consideration payable, current		3,028			9,982			4,434			5,184
Operating lease liability, current		1,394			1,171			1,911			1,857
Lease obligations under finance leases, current		384			22			275			521
Corporate income tax payable		13,189			9,621			45,934			23,077
Other current liabilities		3,613			-			1,608			2,599
Current liabilities from discontinued operations								1,466			9,111
		140,403			61,044			133,489			137,905
Non-Current Liabilities
Loans payable, non-current		180,781			176,306			180,400			145,852
Contingent consideration payable, non-current		2,620			2,553
Operating lease liability, non-current		31,680			30,573			35,207			31,545
Lease obligations under finance leases, non-current		4,794			181			2,139			6,713
Warrant liability		6,176			54,986
Derivative liability								5,750			711
Convertible debt								6,447			—
Deferred income tax liability		73,087			14,269			35,596			30,700
Financing obligations		11,606			—			10,754			11,198
Other long term liabilities		12,502			13,068			16,367			15,792
		323,246			291,936			292,660			242,511
Total Liabilities		463,649			352,980			426,149			380,416
Commitments and Contingencies
Shareholders' Equity
Share Capital
Series A, convertible preferred stock, no par value, unlimited shares authorized; 12,658 and 13,708 shares outstanding as of June 30, 2022 and December 31, 2021 respectively		—			—
Series B, convertible preferred stock, no par value, unlimited shares authorized; 610 and 610 shares outstanding as of June 30, 2022 and December 31, 2021 respectively		—			—
Series C, convertible preferred stock, no par value, unlimited shares authorized; nil and 36 shares outstanding as of June 30, 2022 and December 31, 2021 respectively		—			—
Series D, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2022 and December 31, 2021 respectively		—			—
Proportionate voting shares, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2022 and December 31, 2021 respectively		—			—
Exchangeable shares, no par value, unlimited shares authorized; 52,395,071 and 38,890,571 shares outstanding as of June 30, 2022 and December 31, 2021 respectively		—			—
Common stock, no par value, unlimited shares authorized; 252,707,325 and 190,930,800 shares outstanding as of June 30, 2022 and December 31, 2021 respectively		0			0
Series A, convertible preferred stock, no par value, unlimited shares authorized; 12,350 and 12,608 shares outstanding as of June 30, 2023 and December 31, 2022, respectively								—			—
Series B, convertible preferred stock, no par value, unlimited shares authorized; 600 and 600 shares outstanding as of June 30, 2023 and December 31, 2022, respectively								—			—
Series C, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2023 and December 31, 2022, respectively								—			—
Series D, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2023 and December 31, 2022, respectively								—			—
Proportionate voting shares, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2023 and December 31, 2022, respectively								—			—
Exchangeable shares, no par value, unlimited shares authorized; 63,492,038 and 76,996,538 shares outstanding as of June 30, 2023 and December 31, 2022, respectively								—			—
Common shares, no par value, unlimited shares authorized; 286,807,780 and 259,624,531 shares outstanding as of June 30, 2023 and December 31, 2022, respectively								—			—
Additional paid in capital		854,948			535,418			945,926			934,972
Accumulated other comprehensive income (loss)		(1,063	)		2,823
Accumulated other comprehensive income								1,330			2,085
Accumulated deficit		(315,132	)		(314,654	)		(653,623	)		(618,260	)
Non-controlling interest		6,215			5,367			1,966			2,374
Total Shareholders' Equity		544,968			228,954			295,599			321,171
Total Liabilities and Shareholders' Equity	$	1,008,617		$	581,934		$	721,748		$	701,587

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

TerrAscend Corp.

Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income ~~(Loss)~~

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)


	For the Three Months Ended						For the Six Months Ended							For the Three Months Ended							For the Six Months Ended
	June 30, 2022			June 30, 2021				June 30, 2022			June 30, 2021				June 30, 2023			June 30, 2022				June 30, 2023			June 30, 2022
Revenue	$	65,367		$	61,977			$	115,812		$	118,473			$	72,437		$	64,221			$	142,157		$	113,281
Excise and cultivation tax		(563	)		(3,254	)			(1,349	)		(6,396	)			(313	)		(261	)			(635	)		(736	)
Revenue, net		64,804			58,723				114,463			112,077				72,124			63,960				141,522			112,545

Cost of Sales		41,811			23,888				76,330			42,300				35,898			40,009				71,396			72,970

Gross profit		22,993			34,835				38,133			69,777				36,226			23,951				70,126			39,575

Operating expenses:
General and administrative		33,981			20,750				56,533			41,142				30,476			32,925				58,206			54,349
Amortization and depreciation		3,016			1,844				5,634			3,717				2,242			2,581				4,271			4,756
Impairment of property and equipment																10			—				345			—
Total operating expenses		36,997			22,594				62,167			44,859				32,728			35,506				62,822			59,105

(Loss) income from operations		(14,004	)		12,241				(24,034	)		24,918
Other expense (income)
Revaluation of contingent consideration		34			(7	)			153			2,990
(Gain) loss on fair value of warrants and purchase option derivative asset		(47,345	)		19,891				(53,058	)		25,301
Income (loss) from operations																3,498			(11,555	)			7,304			(19,530	)
Other (income) expense
Loss from revaluation of contingent consideration																—			34				—			153
Gain on fair value of warrants and purchase option derivative asset																(215	)		(47,345	)			(653	)		(53,058	)
Finance and other expenses		13,902			8,919				20,758			15,309				8,171			13,663				18,258			20,318
Transaction and restructuring costs		627			432				1,242			432				389			627				392			1,242
Impairment of goodwill		—			5,007				—			5,007
Impairment of intangible assets		—			3,633				—			3,633
Unrealized and realized foreign exchange loss		(306	)		3,055				50			5,838
Unrealized and realized loss (gain) on investments		234			(5,964	)			234			(6,192	)
Income (loss) before provision from income taxes		18,850			(22,725	)			6,587			(27,400	)
Unrealized and realized foreign exchange (gain) loss																(101	)		(315	)			(132	)		41
Unrealized and realized loss on investments																1,661			234				2,360			234
(Loss) Income from continuing operations before provision from income taxes																(6,407	)		21,547				(12,921	)		11,540
Provision for income taxes		4,688			6,937				8,431			16,373				6,448			4,688				19,112			8,431
Net income (loss)	$	14,162		$	(29,662	)		$	(1,844	)	$	(43,773	)
Net (loss) income from continuing operations															$	(12,855	)	$	16,859			$	(32,033	)	$	3,109

Discontinued operations:
Loss from discontinued operations, net of tax															$	(621	)	$	(2,697	)		$	(4,212	)	$	(4,953	)
Net (loss) income															$	(13,476	)	$	14,162			$	(36,245	)	$	(1,844	)

Foreign currency translation		280			(3,025	)			3,887			(5,214	)			408			280				755			3,887
Comprehensive income (loss)	$	13,882		$	(26,637	)		$	(5,731	)	$	(38,559	)
Comprehensive (loss) income															$	(13,884	)	$	13,882			$	(37,000	)	$	(5,731	)

Net income (loss) attributable to:
Net (loss) income from continuing operations attributable to:
Common and proportionate Shareholders of the Company	$	13,217		$	(30,660	)		$	(3,140	)	$	(44,834	)		$	(14,998	)	$	15,914			$	(36,362	)	$	1,813
Non-controlling interests		945			998				1,296			1,061			$	2,143		$	945			$	4,329		$	1,296

Comprehensive income (loss) attributable to:
Comprehensive (loss) income from continuing operations attributable to:
Common and proportionate Shareholders of the Company	$	12,937		$	(27,635	)		$	(7,027	)	$	(39,620	)		$	(16,027	)	$	12,937			$	(41,329	)	$	(7,027	)
Non-controlling interests		945			998				1,296			1,061			$	2,143		$	945			$	4,329		$	1,296

Net income (loss) per share, basic and diluted
Net income (loss) per share - basic	$	0.05		$	(0.17	)		$	(0.01	)	$	(0.25	)
Net (loss) income per share
Net (loss) income per share - basic:
Continuing operations															$	(0.05	)	$	0.06			$	(0.13	)	$	0.01
Discontinued operations															$	-		$	(0.01	)		$	(0.02	)	$	(0.02	)
Net (loss) income per share - basic															$	(0.05	)	$	0.05			$	(0.15	)	$	(0.01	)
Weighted average number of outstanding common and proportionate voting shares		252,305,425			182,369,839				231,829,926			176,901,119				275,186,279			252,305,425				271,223,233			231,829,926
Net income (loss) per share - diluted	$	0.05		$	(0.17	)		$	(0.01	)	$	(0.25	)

Net (loss) income per share - diluted:
Continuing operations															$	(0.05	)	$	0.06			$	(0.13	)	$	0.01
Discontinued operations																—		$	(0.01	)		$	(0.02	)	$	(0.02	)
Net (loss) income per share - diluted															$	(0.05	)	$	0.05			$	(0.15	)	$	(0.01	)
Weighted average number of outstanding common and proportionate voting shares, assuming dilution		257,883,711			182,369,839				231,829,926			176,901,119				275,186,279			257,883,711				271,223,233			231,829,926

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

TerrAscend Corp.

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)


	Number of Shares
					Convertible Preferred Stock
	Common Shares		Exchangeable Shares		Series A		Series B			Common Shares Equivalent			Additional paid in capital			Accumulated other comprehensive income (loss)				Accumulated deficit				Non-controlling interest				Total
Balance at March 31, 2023		274,653,743		63,492,038		12,350		600			351,095,985		$	936,404		$	1,738			$	(641,517	)		$	2,676			$	299,301
Shares issued - stock options, warrant and RSU exercises		1,078		—		—		—			1,078			—			—				—				—				—
Shares, options and warrants issued - acquisitions		5,442,282		—		—		—			5,442,282			9,524			—				—				—				9,524
Shares, options and warrants issued - legal settlement		130,000		—		—		—	—		130,000	—		201			—		—		—		—		—		—		201
Shares issued - conversion		—		—		—		—			—			—			—				—				—				—
Private placement net of share issuance costs		6,580,677		—		—		—	—		6,580,677	—		7,507			—		—		—		—		—		—		7,507
Share-based compensation expense		—		—		—		—			—			1,981			—				—				—				1,981
Options and warrants expired/forfeited		—		—		—		—			—			(3,514	)		—				3,514				—				—
Capital distributions		—		—		—		—			—			—			—				—				(1,531	)			(1,531	)
Acquisition of non-controlling interest		—		—		—		—			—			(6,177	)		—				—				(1,323	)			(7,500	)
Net (loss) income for the period		—		—		—		—			—			—			—				(15,620	)			2,144				(13,476	)
Foreign currency translation		—		—		—		—			—			—			(408	)			—				—				(408	)
Balance at June 30, 2023		286,807,780		63,492,038		12,350		600	—		363,250,022	—		945,926			1,330		—		(653,623	)	—		1,966		—		295,599


	Number of Shares
					Convertible Preferred Stock
	Common Shares		Exchangeable Shares		Series A			Series B		Common Shares Equivalent		Additional paid in capital			Accumulated other comprehensive income (loss)			Accumulated deficit			Non-controlling interest			Total
Balance at March 31, 2022		251,971,226		52,395,071		13,358			610		318,334,501	$	850,386		$	(783	)		(329,855	)		5,491		$	525,239
Shares issued - stock option, warrant and RSU exercises		36,099		—		—			—		36,099		1,041			—			—			—			1,041
Shares issued - conversion		700,000		—		(700	)		—		—		—			—			—			—			—
Shares issued - liability settlement		—		—		—			—		—		—			—			—			—			—
Share-based compensation expense		—		—		—			—		—		4,463			—			—			—			4,463
Options expired/forfeited		—		—		—			—		—		(1,506	)		—			1,506			—			—
Capital contribution		—		—		—			—		—		564			—			—			(221	)		343
Net income for the period		—		—		—			—		—		—			—			13,217			945			14,162
Foreign currency translation		—		—		—			—		—		—			(280	)		—			—			(280	)
Balance at June 30, 2022		252,707,325		52,395,071		12,658			610		318,370,600	$	854,948		$	(1,063	)	$	(315,132	)	$	6,215		$	544,968

TerrAscend Corp.

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity ~~(Deficit)~~(Continued)

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)


	Number of Shares
						Convertible Preferred Stock
	Common Shares		Exchangeable Shares			Series A			Series B		Common Shares Equivalent		Additional paid in capital			Accumulated other comprehensive income (loss)			Accumulated deficit			Non-controlling interest			Total
Balance at December 31, 2022		259,624,531		76,996,538			12,608			600		349,829,273	$	934,972		$	2,085		$	(618,260	)	$	2,374		$	321,171
Shares issued - stock options, warrant and RSU exercises		393,924		—			—			—		393,924		81			—			—			—			81
Shares, options and warrants issued - acquisitions		5,913,963		—			—			—		5,913,963		10,267			—			—			—			10,267
Shares, options and warrants issued - legal settlement		532,185		—			—			—		532,185		794			—			—			—			794
Shares issued - conversion		13,762,500		(13,504,500	)		(258	)		—		—		—			—			—			—			—
Private placement net of share issuance costs		6,580,677		—			—			—		6,580,677		7,507			—			—			—			7,507
Share-based compensation expense		—		—			—			—		—		3,694			—			—			—			3,694
Options and warrants expired/forfeited		—		—			—			—		—		(5,212	)		—			5,212			—			—
Capital distributions		—		—			—			—		—		—			—			—			(3,415	)		(3,415	)
Acquisition of non-controlling interest		—		—			—			—		—		(6,177	)		—			—			(1,323	)		(7,500	)
Net (loss) income for the period		—		—			—			—		—		—			—			(40,575	)		4,330			(36,245	)
Foreign currency translation		—		—			—			—		—		—			(755	)		—			—			(755	)
Balance at June 30, 2023		286,807,780		63,492,038			12,350			600		363,250,022	$	945,926		$	1,330		$	(653,623	)	$	1,966		$	295,599

~~Three months ended~~


	Number of Shares																														Number of Shares
					Convertible Preferred Stock																														Convertible Preferred Stock
	Common Stock		Exchangeable Shares		Series A			Series B		Series C		Series D		Common Shares Equivalent		Additional paid in capital			Accumulated other comprehensive income (loss)			Accumulated deficit			Non-controlling interest			Total			Common Shares		Exchangeable Shares		Series A			Series B		Common Shares Equivalent		Additional paid in capital			Accumulated other comprehensive income (loss)			Accumulated deficit			Non-controlling interest			Total
Balance at March 31, 2022		251,971,226		52,395,071		13,358			610		—		—		318,334,501	$	850,386		$	(783	)		(329,855	)		5,491		$	525,239
Balance at December 31, 2021																																190,930,800		38,890,571		13,708			610		244,175,394	$	535,418		$	2,823			(314,654	)		5,367		$	228,954
Shares issued - stock option, warrant and RSU exercises		36,099		—		—			—		—		—		36,099		1,041			—			—			—			1,041			9,336,728		—		—			—		9,336,728		25,743			—			—			—			25,743
Shares issued - acquisitions																																51,349,978		13,504,500		—			—		64,854,478		288,044			—			—			—			288,044
Shares issued - liability settlement																																4,000		—		—			—		4,000		22			—			—			—			22
Shares issued- conversion		700,000		—		(700	)		—		—		—		—		—			—			—			—			—			1,085,819		—		(1,050	)		—		—		—			—			—			—			—
Share-based compensation expense		—		—		—			—		—		—		—		4,463			—			—			—			4,463			—		—		—			—		—		7,819			—			—			—			7,819
Options expired/forfeited		—		—		—			—		—		—		—		(1,506	)		—			1,506			—			—			—		—		—			—		—		(2,662	)		—			2,662			—			—
Capital Contribution		—		—		—			—		—		—		—		564			—			—			(221	)		343
Net income for the period		—		—		—			—		—		—		—		—			—			13,217			945			14,162
Conversion of convertible debt																																—		—		—			—		—		564			—			—			—			564
Capital contribution																																—		—		—			—		—		—			—			—			(448	)		(448	)
Net (loss) income for the period																																—		—		—			—		—		—			—			(3,140	)		1,296			(1,844	)
Foreign currency translation		—		—		—			—		—		—		—		—			(280	)		—			—			(280	)		—		—		—			—		—		—			(3,886	)		—			—			(3,886	)
Balance at June 30, 2022		252,707,325		52,395,071		12,658			610		—		—		318,370,600	$	854,948		$	(1,063	)	$	(315,132	)	$	6,215		$	544,968			252,707,325		52,395,071		12,658			610		318,370,600	$	854,948		$	(1,063	)	$	(315,132	)	$	6,215		$	544,968

Number of Shares

Convertible Preferred Stock

Common Stock

Exchangeable Shares

Proportionate Voting Shares

Series A

Series B

Series C

Series D

Common Shares Equivalent

Additional paid in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Non-controlling interest

Total

Balance at March 31, 2021

178,956,366

38,890,571

—

14,008

610

—

—

232,464,485

$
513,643

$
(1,473
)

(332,715
)

3,705

$
183,160

Shares issued - stock option, warrant and RSU exercises

1,676,567

—

—

—

—

—

1,676,567

7,310

—

—

—

7,310

Shares issued - acquisitions

3,464,870

—

—

—

—

—

3,464,870

34,427

—

—

—

34,427

Shares issued - liability settlement

5,000

—

—

—

—

—

5,000

57

—

—

—

57

Shares issued- conversion

300,000

—

(300
)

—

—

—

—

—

—

—

—

—

Share-based compensation expense

—

—

—

—

—

—

—

4,648

—

—

—

4,648

Return of capital

—

—

—

—

—

—

—

—

—

—

(223
)

(223
)
Net loss for the period

—

—

—

—

—

—

—

—

—

(30,660
)

998

(29,662
)
Foreign currency translation

—

—

—

—

—

—

—

—

3,025

—

—

3,025

Balance at June 30, 2021

184,402,803

38,890,571

—

13,708

610

—

—

237,610,922

$
560,085

$
1,552

$
(363,375
)

$
4,480

$
202,742

~~Six months ended~~

Number of Shares

Convertible Preferred Stock

Common Stock

Exchangeable Shares

Series A

Series B

Series C

Series D

Common Shares Equivalent

Additional paid in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Non-controlling interest

Total

Balance at December 31, 2021

190,930,800

38,890,571

13,708

610

36

—

244,175,394

$
535,418

$
2,823

(314,654
)

5,367

$
228,954

Shares issued - stock option, warrant and RSU exercises

9,336,728

—

—

—

—

—

9,336,728

25,743

—

—

—

25,743

Shares, options and warrants issued- acquisitions

51,349,978

13,504,500

—

—

—

—

64,854,478

288,044

—

—

—

288,044

Shares issued- liability settlement

4,000

—

—

—

—

—

4,000

22

—

—

—

22

Shares issued- conversion

1,085,819

—

(1,050
)

—

(36
)

—

—

—

—

—

—

—

Share-based compensation expense

—

—

—

—

—

—

—

7,819

—

—

—

7,819

Options expired/forfeited

—

—

—

—

—

—

—

(2,662
)

—

2,662

—

—

Capital Contribution

—

—

—

—

—

—

—

564

—

—

(448
)

116

Net loss for the period

—

—

—

—

—

—

—

—

—

(3,140
)

1,296

(1,844
)
Foreign currency translation

—

—

—

—

—

—

—

—

(3,886
)

—

—

(3,886
)
Balance at June 30, 2022

252,707,325

52,395,071

12,658

610

—

—

318,370,600

$
854,948

$
(1,063
)

$
(315,132
)

$
6,215

$
544,968

Number of Shares

Convertible Preferred Stock

Common Stock

Exchangeable Shares

Proportionate Voting Shares

Series A

Series B

Series C

Series D

Common Shares Equivalent

Additional paid in capital

Accumulated other comprehensive income (loss)

Accumulated deficit

Non-controlling interest

Total

Balance at December 31, 2020

79,526,785

38,890,571

76,307

14,258

710

—

—

209,692,379

$
305,138

$
(3,662
)

(318,594
)

3,802

$
(13,316
)
Shares issued - stock option, warrant and RSU exercises

3,647,503

—

—

—

—

87

1,315

5,048,796

33,168

—

—

—

33,168

Shares issued - acquisitions

3,464,870

—

—

—

—

—

—

3,464,870

34,427

—

—

—

34,427

Shares issued - liability settlement

5,000

—

—

—

—

—

—

5,000

57

—

—

—

57

Private placement net of share issuance costs

18,115,656

—

—

—

—

—

—

18,115,656

173,477

—

—

—

173,477

Shares issued- conversion

78,358,768

—

(76,307
)

(550
)

(100
)

(87
)

(1,315
)

—

—

—

—

—

—

Share-based compensation expense

—

—

—

—

—

—

—

—

8,215

—

—

—

8,215

Options expired/forfeited

—

—

—

—

—

—

—

—

(53
)

—

53

—

—

Conversion of convertible debt

1,284,221

—

—

—

—

—

—

1,284,221

5,656

—

—

—

5,656

Return of capital

—

—

—

—

—

—

—

—

—

—

—

(383
)

(383
)
Net loss for the period

—

—

—

—

—

—

—

—

—

—

(44,834
)

1,061

(43,773
)
Foreign currency translation

—

—

—

—

—

—

—

—

—

5,214

—

—

5,214

Balance at June 30, 2021

184,402,803

38,890,571

—

13,708

610

—

—

237,610,922

$
560,085

$
1,552

$
(363,375
)

$
4,480

$
202,742

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements

TerrAscend Corp.

Unaudited Interim Condensed Consolidated Statements of Cash Flows

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

For the Six Months Ended

June 30, 2022

June 30, 2021

Operating activities

Net loss
$

(1,844
)
$

(43,773
)
Adjustments to reconcile net income to net cash provided by (used in) operating activities

Non-cash write downs of inventory

8,495

699

Accretion expense

1,936

(544
)
Depreciation of property and equipment and amortization of intangible assets

12,131

7,050

Amortization of operating right-of-use assets

1,074

2,269

Share-based compensation

7,819

8,215

Deferred income tax (recovery) expense

(787
)

285

(Gain) loss on fair value of warrants and purchase option derivative

(53,058
)

25,301

Revaluation of contingent consideration

153

2,990

Impairment of intangible assets

—

3,633

Impairment of goodwill

—

5,007

Loss on disposal of fixed assets

929

—

Release of indemnification asset

3,973

3,796

Forgiveness of loan principal and interest

—

(766
)
Unrealized and realized foreign exchange loss

50

5,838

Unrealized and realized loss (gain) on investments

234

(6,192
)
Changes in operating assets and liabilities

Receivables

475

(950
)
Inventory

208

(9,879
)
Prepaid expense and deposits

1,474

(507
)
Deposits

206

—

Other assets

461

389

Accounts payable and accrued liabilities and other payables

(8,299
)

639

Operating lease liability

(614
)

(1,889
)
Other liability

(10,353
)

—

Contingent consideration payable

(410
)

(11,394
)
Corporate income tax payable

5

(293
)
Deferred revenue

766

—

Net cash used in operating activities

(34,976
)

(10,076
)
Investing activities

Investment in property and equipment

(12,500
)

(10,856
)
Investment in intangible assets

(1,330
)

(40
)
Principal payments received on lease receivable

392

359

Distributions of earnings from associates

—

469

Deposits for property and equipment

(10,036
)

(10,583
)
Deposits for business acquisition

(852
)

—

Payments made for land contracts

(429
)

—

Cash received on acquisition

24,716

—

Cash portion of consideration paid in acquisitions, net of cash acquired

—

(42,736
)
Net cash used in investing activities

(39
)

(63,387
)
Financing activities

Proceeds from options and warrants exercised

24,158

12,921

Loan principal paid

(5,203
)

—

Loan amendment fee paid

(1,200
)

—

Proceeds from loans payable

—

766

Cash distributions to NJ partners

(1,436
)

—

Capital contributions received (paid) from (to) non-controlling interests

(448
)

(383
)
Payments of contingent consideration

(6,630
)

(18,274
)
Payments made for financing obligations

(460
)

—

Proceeds from private placement, net of share issuance costs

—

173,477

Net cash provided by financing activities

8,781

168,507

Net (decrease) increase in cash and cash equivalents and restricted cash during the period

(26,234
)

95,044

Net effects of foreign exchange

(4,377
)

(89
)
Cash and cash equivalents and restricted cash, beginning of period

79,642

59,226

Cash and cash equivalents and restricted cash, end of period
$

49,031

$

154,181

Supplemental disclosure with respect to cash flows

Income taxes paid
$

9,213

$

16,381

Interest paid
$

14,641

$

13,290

Lease termination fee paid
$

3,300

-

Non-cash transactions

Equity and warrant liability issued as consideration for acquisition
$

294,800

$

34,427

Promissory note issued as consideration for acquisitions
$

-

$

6,750

Shares issued for liability settlement
$

22

$

57

Accrued capital purchases
$

9,776

$

336


	For the Six Months Ended
		June 30, 2023			June 30, 2022
Operating activities
Net (loss) income from continuing operations		$	(32,033	)	$	3,109
Adjustments to reconcile net (loss) income to net cash used in operating activities
Non-cash write downs of inventory			1,081			8,495
Accretion expense			5,673			1,708
Depreciation of property and equipment and amortization of intangible assets			9,761			11,253
Amortization of operating right-of-use assets			932			1,074
Share-based compensation			3,694			7,819
Deferred income tax expense			815			(787	)
Gain on fair value of warrants and purchase option derivative			(653	)		(53,058	)
Loss on disposal of fixed assets			345			—
Revaluation of contingent consideration			—			153
Loss on disposal of fixed assets			—			929
Release of indemnification asset			—			3,973
Unrealized and realized foreign exchange (gain) loss			(132	)		41
Unrealized and realized loss on investments / derivatives			2,410			234
Changes in operating assets and liabilities
Receivables			295			(445	)
Inventory			(7,851	)		208
Prepaid expense and other current assets			(319	)		1,434
Deposits			431			206
Other assets			714			461
Accounts payable and accrued liabilities and other payables			4,089			(7,840	)
Operating lease liability			(337	)		(614	)
Other liability			1,085			(10,353	)
Contingent consideration payable			—			(410	)
Corporate income tax payable			22,127			5
Deferred revenue			157			766
Net cash provided by (used in) operating activities- continuing operations			12,284			(31,639	)
Net cash (used in) operating activities- discontinued operations			(3,164	)		(3,337	)
Net cash provided by (used in) operating activities			9,120			(34,976	)

Investing activities
Investment in property and equipment			(4,504	)		(12,500	)
Investment in intangible assets			(262	)		(1,330	)
Principal payments received on lease receivable			104			392
Receipt of convertible debenture payment			738			—
Deposits for property and equipment			—			(10,036	)
Deposits for business acquisition			—			(852	)
Payment for land contracts			(769	)		(429	)
Cash portion of consideration paid in acquisitions, net of cash of acquired			(14,469	)		24,716
Net cash (used in) investing activities- continuing operations			(19,162	)		(39	)
Net cash provided by investing activities- discontinued operations			14,285			—
Net cash (used in) investing activities			(4,877	)		(39	)

Financing activities
Transfer of Employee Retention Credit			12,677			—
Proceeds from loan payable, net of transaction costs			23,872			—
Proceeds from options and warrants exercised			81			24,158
Loan principal paid			(40,359	)		(4,968	)
Loan amendment fee paid and prepayment premium paid			(1,178	)		(1,200	)
Cash distributions to partners			(3,415	)		(1,436	)
Capital contributions paid to non-controlling interests			—			(448	)
Payments of contingent consideration			—			(6,630	)
Proceeds from private placement, net of share issuance costs			19,218			—
Payments made for financing obligations and finance lease			(941	)		(460	)
Net cash provided by financing activities- continuing operations			9,955			9,016
Net cash (used in) financing activities- discontinued operations			(5,539	)		(235	)
Net cash provided by financing activities			4,416			8,781

Net increase in cash and cash equivalents and restricted cash during the period			8,659			(26,234	)
Net effects of foreign exchange			(901	)		(4,377	)
Cash and cash equivalents and restricted cash, beginning of the period			26,763			79,642
Cash and cash equivalents and restricted cash, end of the period		$	34,521		$	49,031

Supplemental disclosure with respect to cash flows
Income taxes (refund received) paid		$	(4,582	)	$	9,213
Interest paid		$	9,259		$	14,641
Lease termination fee paid		$	-		$	3,300
Non-cash transactions
Equity and warrant liability issued as consideration for acquisition		$	10,267		$	294,800
Shares issued for legal and liability settlement		$	794		$	22
Accrued capital purchases		$	529		$	9,776

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

1. Nature of operations

TerrAscend Corp. (“TerrAscend” or the “Company”) was incorporated under the Ontario Business Corporations Act on March 7, 2017. TerrAscend provides cannabis products, brands, and services into the United States ~~("US"~~(“U.S.”) and ~~Canada~~Canadian cannabinoid markets where cannabis production or consumption has been legalized for therapeutic or adult use. TerrAscend operates a number of synergistic businesses, including Gage Growth ~~Corp.~~ ("Gage"), a cultivator, processor and retailer in ~~Michigan,~~Michigan; KISA Enterprises MI, LLC and KISA Holdings LLC (collectively "Pinnacle"); The Apothecarium (“The Apothecarium”), a cannabis dispensary with several retail locations in California, Pennsylvania and New Jersey; TerrAscend NJ, LLC ("TerrAscend NJ"), a cultivator, processor and retailer with operations in New ~~Jersey,~~Jersey; Ilera Healthcare (“Ilera”), Pennsylvania’s medical cannabis cultivator, processor and dispenser; vertically integrated operations in Maryland which include HMS Health, LLC and HMS Processing, LLC (collectively “HMS”), a ~~medical~~ cannabis cultivator and processor, ~~based in Maryland;~~Allegany Medical Marijuana Dispensary ("AMMD"), Peninsula Alternative Health ("Peninsula"), Blue Ridge Wellness ("Blue Ridge"), and Herbiculture Inc. ("Herbiculture"); Valhalla Confections, a ~~manufacturer of~~ cannabis-infused ~~edibles;~~edibles brand; and State Flower, a California-based cannabis producer operating a licensed cultivation facility in San ~~Francisco; and Arise Bioscience Inc., a manufacturer and distributor~~Francisco. Notwithstanding various states in the U.S. which have implemented medical marijuana laws, or which have otherwise legalized the use of ~~hemp-derived products.~~cannabis, the use of cannabis remains illegal under U.S. federal law for any purpose, by way of the Controlled Substances Act of 1970.

~~The~~

Effective July 4, 2023, the Company ~~was listed~~commenced trading of its common shares on the Toronto Stock Exchange ("TSX"), under the ticker symbol "TSND". Previously from May 3, 2017 to June 30, 2023, common shares of the Company were traded on the Canadian ~~Stock~~Securities Exchange ~~effective May 3, 2017, having the~~under ticker symbol ~~TER and effective October 22, 2018,~~"TER". The common shares of the Company began trading on OTCQX on October 22, 2018 under the ticker symbol ~~TRSSF.~~"TRSSF" and changed its ticker symbol to "TSNDF" effective July 6, 2023. The Company’s registered office is located at ~~3610 Mavis Road,~~77 City Centre Drive, Suite 501, Mississauga, Ontario, ~~L5C 1W2.~~L5B 1M5.

Summary of significant accounting policies

(a)

Basis of presentation

These unaudited interim condensed consolidated financial statements ~~as of and for the three and six months ended June 30, 2022 and 2021~~included herein (the “Consolidated Financial Statements”) of the Company and its subsidiaries were prepared in accordance with ~~accounting principles generally accepted in the United States of America (“GAAP”~~U.S. Generally Accepted Accounting Principles ("GAAP").

The accompanying condensed consolidated financial statements contained in this report are unaudited. In the opinion of management, these unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and notes thereto of the Company and include all adjustments, consisting only of normal recurring adjustments, considered necessary for the fair presentation of the Company’s financial position and operating results. The results for the three and six months ended June 30, ~~2022 and 2021~~2023 are not necessarily indicative of the operating results for the year ended December 31, ~~2022,~~2023, or any other interim or future periods.

The accompanying unaudited interim condensed consolidated financial statements have been prepared on the going concern basis, under the historical cost convention, except for certain financial instruments that are measured at fair value as described herein. At June 30, 2023, TerrAscend had an accumulated deficit of $653,623. During the three and six months ended June 30, 2023, TerrAscend incurred a net loss from continuing operations of $12,855 and $32,033, respectively. Additionally, as of June 30, 2023 the Company’s current liabilities exceed its current assets. Therefore, the Company expects that it will need additional capital to continue to fund its operations.

The aforementioned indicators raise substantial doubt about TerrAscend's ability to continue as a going concern for at least one year from the issuance of these financial statements. The Company believes this concern is mitigated by steps to improve its operations and cash position, including: (i) identifying access to future capital required to meet the Company’s on-going obligations, (ii) improved cashflow growth from the Company's consolidated operations, particularly in New Jersey and most recently Maryland with conversion to adult use sales, and (iii) various cost and efficiency improvements.

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto of the Company for the year ended December 31, ~~2021~~2022 contained in the Company's ~~2021~~2022 Form 10-K. There were no significant changes to the policies disclosed in Note 2 of the summary of significant accounting policies of the Company’s audited consolidated financial statements for the year ended December 31, ~~2021~~2022 in the Company's ~~2021~~2022 Form ~~10-K.~~10-K other than the new estimate disclosed in Note 3 of the financial statements.

~~Accounts receivable, net~~Consolidation

June 30, 2022

December 31, 2021

Trade receivables

$
22,341

$
14,684

Sales tax receivable

559

358

Other receivables

437

370

Provision for sales returns

(316
)

(157
)
Expected credit losses

(832
)

(335
)
Total receivables, net

$
22,189

$
14,920

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

~~Sales tax receivable represents input tax credits arising~~The Company consolidates entities in which it has a controlling financial interest by evaluating whether the entity is a voting interest entity (“VOE”) or a variable interest entity (“VIE”).

As a part of the TSX listing, the Company reorganized its ownership in subsidiaries to segregate the Company’s Canadian cannabis operations from ~~sales tax levied~~its operations in the United States (the "Reorganization"). After the Reorganization, the Company owns 95% of its Canadian business. The Company continues to consolidate both its Canadian and its U.S. cannabis operation under two different consolidation models.

Voting Interest Entities

A VOE is an entity in which (1) the total equity investment at risk is deemed sufficient to absorb the expected losses of the entity, (2) the at-risk equity holders, as a group, have all of the characteristics of a controlling financial interest and (3) the entity is structured with substantive voting rights. The Company consolidates the Canadian operations under a VOE model based on the ~~supply~~controlling financial interest obtained through common shares with substantive voting rights.

Variable Interest Entities

A VIE is an entity that lacks one or more characteristics of ~~goods purchased~~a controlling financial interest defined under the voting interest model. The Company consolidates VIE when it has a variable interest that provide it with (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or ~~services~~the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits).

As a result of the Company's TSX listing effort, TerrAscend Growth Corp., a wholly owned subsidiary of the Company, has issued $1 million of Class A shares to an investor. See Note 10 for accounting treatment of Class A shares. The Company’s ownership in Class B shares, representing 100% of the issued and outstanding shares of TerrAscend Growth Corp., were exchanged for non-voting, non-participating exchangeable shares of TerrAscend Growth Corp. Simultaneously, the Company entered into a protection agreement with TerrAscend Growth Corp. that contains certain negative covenants that are designed to preserve the value of the non-voting shares until such time as they are converted into common shares. The Company determined TerrAscend Growth Corp. is a VIE as all the Company’s US activities continue to be conducted on behalf of the Company which has disproportionately few voting rights. After conducting an analysis of the following VIE factors; purpose and design of the VIE, the protection agreement in place, the board structure of TerrAscend Growth Corp., and substantive kick-out rights of the Class A shareholders, it was determined that the Company has the power to direct the activities of TerrAscend Growth Corp. In addition, given the structure of the Class A shares where all of the losses and substantially all of the benefits of TerrAscend Growth Corp. are absorbed by the Company, the Company consolidates as the primary beneficiary in accordance with ASC 810 Consolidation. Management has applied significant judgment on the decision to consolidate its VIE's based on the facts and circumstances noted above.

The Company's U.S. operations are consolidated through the VIE model. Therefore, substantially all of the Company's current assets, non-current assets, current liabilities and non-current liabilities are consolidated through the VIE model. The Company's assets and liabilities that are not consolidated through the VIE model include convertible debt, derivative liability and assets and liabilities from discontinued operations. The Company also consolidates a minimal amount of assets and liabilities within Canada, see Note 21 for more information.

Accounts receivable, net


	June 30, 2023			December 31, 2022
Trade receivables	$	19,213		$	14,786
Sales tax receivable		120			277
Other receivables		994			17,936
Expected credit losses		(10,849	)		(10,556	)
Total receivables, net	$	9,478		$	22,443

For the year ended December 31, 2022, the Company has an Employee Retention Credit ("ERC") for qualified wages of $14,903 which was included in other receivables in the table above at December 31, 2022. During January 2023, the Company received $12,667, pursuant to a financing agreement with a third-party lender. In exchange, the Company assigned to the lender its interests in ~~Canada. Other receivables at~~the $14,903 ERC claim that was submitted during December 2022. The difference between the amount of the claim and the amount received from the lender is the employee retention credits transfer fee which is equal to 15% of the total claim amount. The framework prescribed in

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

ASC 860 Transfers and Servicing was reviewed and management has concluded that this should be accounted for as an asset transfer with recourse. This fee is included in finance and other expenses. If the Company does not receive the ERC claim, in whole or in part, the Company is required to repay the related portion of the funds received plus interest of 10% accrued from the date of the financing agreement through the repayment date. The Company’s obligation under the financing agreement will be satisfied upon receipt of the ERC claim or other full repayment. As of June 30, ~~2022~~2023, the lender has received refunds in the amount of $10,059 and ~~December 31, 2021 mainly include amounts due from the sellers~~is awaiting receipt of the ~~Apothecarium.~~remaining refunds. Management has concluded that collection remains probable and no additional recourse obligation was recorded for the six months ended June 30, 2023.


	June 30, 2022			December 31, 2021			June 30, 2023			December 31, 2022
Trade receivables	$	22,341		$	14,684		$	19,213		$	14,786
Less: provision for sales returns and expected credit losses		(1,148	)		(492	)		(10,849	)		(10,556	)
Total trade receivables, net	$	21,193		$	14,192		$	8,364		$	4,230

Of which
Current		8,173			13,282			7,393			4,045
31-90 days		711			569			1,108			614
Over 90 days		13,457			833			10,712			10,127
Less: provision for sales returns and expected credit losses		(1,148	)		(492	)		(10,849	)		(10,556	)
Total trade receivables, net	$	21,193			14,192		$	8,364		$	4,230

The over 90 days aged balance relates mainly to 1one customer ~~who has agreed to a payment plan and the Company has received payments in accordance with the payment plan subsequent to June 30, 2022.~~which was deemed uncollectible.

~~The following is a roll-forward of the provision for sales returns and allowances related to trade accounts receivable:~~

June 30, 2022

December 31, 2021

Beginning of period

$
492

1,782

Provision for sales returns

255

1,125

Expected credit losses

859

357

Write-offs charged against provision

(431
)

(2,772
)
Foreign currency translation adjustments

(27
)

-

Total provision for sales returns and allowances

$
1,148

492

4.5.

Acquisitions

AMMD

On ~~April 8, 2022,~~January 27, 2023, TerrAscend closed the ~~Company entered into~~acquisition of AMMD, a ~~definitive agreement to acquire Allegany Medical Marijuana Dispensary ("AMMD"), a medical~~ dispensary in ~~Maryland from Moose Curve Holdings, LLC.~~Cumberland, Maryland. Under the terms of the agreement, ~~the Company will acquire~~TerrAscend acquired a 100% equity interest in AMMD for total consideration of $10,000 in cash, in addition to ~~acquiring related real estate for $1,700. The transaction is subject to customary closing conditions and regulatory approvals. The Company intends to rebrand the~~ ~~8,000~~ ~~square foot dispensary as The Apothecarium.~~

~~Pinnacle~~

~~On April 14, 2022, the Company entered~~entering into a ~~definitive agreement~~long-term lease with the option to ~~acquire KISA Enterprises MI, LLC~~purchase the real estate. The cash consideration paid included repayments of indebtedness and ~~KISA Holdings, LLC (collectively, "Pinnacle"), a dispensary operator in Michigan, and related real estate, for total consideration~~transaction expenses on behalf of AMMD of $~~28,500~~160 and $29, ~~payable in cash, two promissory notes in an aggregate amount of $~~respectively.~~10,000, and stock. The transaction includes~~ 6 ~~retail dispensary licenses,~~ 5 of which are currently operational and located in the cities of Addison, Buchanan, Camden, Edmore, and Morenci, Michigan. The Company intends to rebrand each of the dispensaries under either the Gage or Cookies retail brand. This transaction is pending approval.

~~Gage~~

On March 10, 2022, in order to expand its footprint in key markets, the Company acquired all of the issued and outstanding subordinate voting shares (or equivalent) of Gage, a cultivator and processor with operations in the Michigan market. Pursuant to the terms of the arrangement agreement, for each Gage subordinate voting share and other equity instruments, including outstanding stock options and warrants, each holder received a ~~0.3001~~ equivalent replacement award of the Company's respective security at the time of closing based on the closing price of the Common Shares on the Canadian Stock Exchange ("CSE") on March 10, 2022. On the acquisition date there was consideration in the form of ~~51,349,978~~ ~~Common Shares valued at $207,871~~, ~~13,504,500~~ ~~exchangeable units valued at $66,591~~, ~~4,940,364~~ ~~replacement stock options with a fair value of $13,147, and~~ ~~282,023~~ ~~replacement warrants with a fair value of $435. Each of the directors, officers and 10% shareholders of Gage entered into voting support and lock-up agreements in which the shares issued to~~

~~TerrAscend Corp.~~

~~Notes to the Unaudited Condensed Consolidated Financial Statements~~

~~(Amounts expressed in thousands of United States dollars, except for per share amounts)~~

~~these individuals are subject to various vesting periods. As such, a restriction discount of $45,336~~ has been placed over the shares subject to lock-up. The fair value of the replacement options and warrants was calculated using the Black Scholes Option Pricing Model combined with the percentage of the vesting period that was completed prior to the acquisition. Additionally, total consideration included warrant liabilities convertible into equity with a fair value of $~~6,756~~.

The following table presents the fair value of assets acquired and liabilities assumed as of the ~~March 10, 2022~~January 27, 2023 acquisition date and allocation of the consideration to net assets acquired:


	$
~~Cash and cash equivalents~~		~~24,716~~
~~Accounts receivable~~		~~8,996~~
~~Inventory~~		~~20,852~~
~~Prepaid expenses and other current assets~~		~~1,855~~
~~Property and equipment~~		~~69,595~~
~~Operating right of use asset~~		~~1,948~~
~~Deposits~~		~~1,147~~
~~Intangible assets~~		~~187,953~~
~~Goodwill~~		~~150,272~~
~~Investments~~		~~4,121~~
~~Accounts payable and accrued liabilities~~		(~~29,871~~	)
~~Corporate income taxes payable~~		(~~5,000~~	)
~~Operating lease liability~~		(~~1,948~~	)
~~Finance lease liability~~		(~~308~~	)
~~Deferred revenue~~		(~~562~~	)
~~Loans payable~~		(~~60,605~~	)
~~Deferred tax liability~~		(~~59,603~~	)
~~Financing obligations~~		(~~12,184~~	)
~~Other liabilities~~		(~~6,574~~	)
~~Net assets acquired~~		~~294,800~~

~~Common shares of TerrAscend~~		~~274,462~~
~~Fair value of other equity instruments~~		~~13,582~~
~~Fair value of warrants classified as liabilities~~		~~6,756~~
~~Total consideration~~		~~294,800~~


Cash and cash equivalents	$	20
Inventory		303
Prepaid expense		4
Operating right of use asset		781
Fixed assets		416
Intangible asset		5,330
Goodwill		6,005
Accounts payable and accrued liabilities		(135	)
Deferred tax liability		(2,021	)
Corporate income taxes payable		(291	)
Operating lease liability		(781	)
Net assets acquired	$	9,631

Cash		10,000
Working capital adjustment		(369	)
Total consideration	$	9,631

The acquired intangible assets include ~~cultivation and processing licenses, as well as retail licenses,~~a medical license, which ~~are~~is treated as a definite-lived intangible ~~assets which are~~asset and amortized over a ~~15 year~~30-year period. ~~The fair value~~

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of ~~the cultivation~~United States dollars, except for share and ~~processing and the retail licenses are $77,198~~ ~~and $53,321, respectively. In addition, the intangible assets include brand intangibles which are treated as indefinite lived intangible assets. The fair value of the brand intangibles is $57,435~~.per share amounts)

The consideration paid reflected the synergies, economies of scale, and workforce. These benefits were not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets. None of the goodwill recognized is expected to be deductible for income tax purposes.

The accounting for this acquisition has been provisionally determined at June 30, ~~2022.~~2023. The fair value of net assets acquired, specifically with respect to inventory, intangible assets, ~~deferred revenue,~~ property and equipment, operating right of use assets, lease liabilities, ~~investments,~~ corporate income taxes payable, deferred tax liability, and goodwill have been determined provisionally and are subject to adjustment. Upon completion of a comprehensive valuation and finalization of the purchase price allocation, the amounts above may be adjusted retrospectively to the acquisition date in future reporting periods. During the 3 months ended June 30, 2023, an adjustment was made to decrease intangible assets by $620 due to new information regarding the fair value at January 27, 2023. This resulted in an increase to goodwill of the same amount.

Costs related to this transaction were $~~3,949~~191, including legal, accounting, due diligence, and other transaction-related expenses. Of the total amount of transaction costs, $~~1,309~~36 ~~was~~and $99 were recorded during the six months ended June 30, 2023 and June 30, 2022, respectively.

On a standalone basis, had the Company acquired the business on January 1, 2023, sales estimates would have been $3,736 for the six months ended June 30, 2023 and net income estimates would have been $1,141. Actual sales and net income for the six months ended June 30, 2023 since the date of acquisition are $3,057 and $897, respectively.

Peninsula

On June 28, 2023, the Company closed the acquisition of Peninsula, a dispensary located in Salisbury, Maryland. Under the terms of the agreement, the Company acquired 100% of the equity interest in Peninsula for total consideration of $14,362 exclusive of assumed financing obligations of $7,698. The consideration was comprised of 5,442,282 common shares of the Company ("Common Shares"), valued at $9,524, a $3,927 secured promissory note at an interest rate of 7.25% maturing on June 28, 2026, and $1,500 in cash, less a working capital adjustment of $589. The cash consideration paid included transaction expenses and repayments of indebtedness on behalf of Peninsula of $290 and $33, respectively. As part of the stock consideration, the Company guaranteed the value of the stock consideration as of the transaction date for a period up to 24 months from the transaction date. This guarantee in ~~transaction~~value is accounted for as a derivative in accordance with ASC 815, Derivatives and ~~restructuring costs in~~Hedging.

The following table presents the ~~consolidated statement~~fair value of ~~operations~~assets acquired and ~~comprehensive income.~~liabilities assumed as of the June 28, 2023 acquisition date and allocation of the consideration to net assets acquired:


Inventory	$	370
Prepaid expense		371
Operating right of use asset		1,168
Fixed assets		68
Intangible asset		21,800
Goodwill		683
Accounts payable and accrued liabilities		(1,123	)
Loans payable		(7,807	)
Operating lease liability		(1,168	)
Net assets acquired	$	14,362

Cash		1,500
Common shares of TerrAscend		9,524
Loans payable		3,927
Working capital adjustment		(589	)
Total consideration	$	14,362

The acquired intangible assets include a medical license, which is treated as a definite-lived intangible asset and amortized over a 30-year period.

910

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

The accounting for this acquisition has been provisionally determined at June 30, 2023. The fair value of net assets acquired, specifically with respect to inventory, intangible assets, property and equipment, operating right of use assets, lease liabilities, deferred tax liability, and goodwill have been determined provisionally and are subject to adjustment. Upon completion of a comprehensive valuation and finalization of the purchase price allocation, the amounts above may be adjusted retrospectively to the acquisition date in future reporting periods.

Costs related to this transaction were $445, including legal, accounting, due diligence, and other transaction-related expenses and were recorded during the six months ended June 30, 2023.

On a standalone basis, had the Company acquired the business on January 1, ~~2022,~~2023, sales estimates would have been $~~41,444~~6,987 for the six months ended June 30, ~~2022~~2023 and net ~~loss~~income estimates would have been $($~~16,959~~1,168). Actual sales and net loss for the six months ended June 30, ~~2022~~2023 since the date of acquisition are $~~28,928~~200 and $($~~7,748~~129), respectively.

Blue Ridge

On June 30, 2023, the Company closed the acquisition of Blue Ridge, a dispensary located in Parkville, Maryland. The Company has plans to relocate Blue Ridge in the next six months to a new, high-traffic retail center. Under the terms of the agreement, the Company acquired a 100% equity interest in Blue Ridge for total consideration of $6,188, comprised of a promissory note of $3,750 at an interest rate of 7.0% maturing on June 30, 2027 and $3,000 in cash, less a working capital adjustment of $562. The cash consideration paid included repayments of indebtedness and transaction expenses on behalf of Blue Ridge of $707 and $281, respectively.

The following table presents the fair value of assets acquired and liabilities assumed as of the June 30, 2023 acquisition date and allocation of the consideration to net assets acquired:


Inventory	$	234
Prepaid expense		192
Operating right of use asset		2,325
Intangible asset		6,410
Goodwill		2,936
Deferred tax liability		(2,653	)
Accounts payable and accrued liabilities		(931	)
Operating lease liability		(2,325	)
Net assets acquired	$	6,188

Cash		3,000
Loans payable		3,750
Working capital adjustment		(562	)
Total consideration	$	6,188

The acquired intangible assets include a medical license, which is treated as a definite-lived intangible asset and amortized over a 30-year period.

The accounting for this acquisition has been provisionally determined at June 30, 2023. The fair value of net assets acquired, specifically with respect to inventory, intangible assets, operating right of use assets, lease liabilities, deferred tax liability, and goodwill have been determined provisionally and are subject to adjustment. Upon completion of a comprehensive valuation and finalization of the purchase price allocation, the amounts above may be adjusted retrospectively to the acquisition date in future reporting periods.

Costs related to this transaction were $163, including legal, accounting, due diligence, and other transaction-related expenses and were recorded during the six months ended June 30, 2023.

On a standalone basis, had the Company acquired the business on January 1, 2023, sales estimates would have been $2,018 for the six months ended June 30, 2023 and net income estimates would have been $383. Actual sales and net loss for the six months ended June 30, 2023 since the date of acquisition are $21 and $84, respectively.

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

Contingent consideration

Contingent consideration recorded relates to the Company’s business acquisitions. Contingent consideration is based upon the potential earnout of the underlying business unit and is measured at fair value using a projection model for the business and the formulaic structure for determining the consideration under the terms of the agreement.

The balance of contingent consideration is as follows:


	State Flower			Apothecarium			KCR		Total			State Flower			Apothecarium			Pinnacle			Total
Carrying amount, December 31, 2021	$	8,360		$	3,028		$	1,147	$	12,535
Carrying amount, December 31, 2022												$	1,406		$	3,028		$	750		$	5,184
Payments of contingent consideration		(7,040	)		—			—		(7,040	)		—			—			(750	)		(750	)
Revaluation of contingent consideration		86			—			67		153
Carrying amount, June 30, 2022	$	1,406		$	3,028		$	1,214	$	5,648
Carrying amount, June 30, 2023												$	1,406		$	3,028			—		$	4,434
Less: current portion		—			(3,028	)		—		(3,028	)		(1,406	)		(3,028	)		—			(4,434	)
Non-current contingent consideration	$	1,406		$	-		$	1,214	$	2,620			—			—			—			—

During the six months ended June 30, ~~2022,~~2023, the Company ~~made payments~~issued 471,681 shares of $~~7,040~~common stock to the sellers of its previously acquired ~~State Flower~~Pinnacle business. The ~~remaining amount will be paid to~~issuance of shares fully settles the ~~sellers of State Flower upon~~$750 earn out consideration provision in the ~~Company's acquisition of the remaining~~ ~~50.1% of State Flower, which is subject to regulatory approval.~~

~~Refer to Note 20 for discussion ofvaluation methods used when determining the fair value of the contingent consideration liability at June 30, 2022, and the changes in fair value during the six months ended June 30, 2022.~~stock purchase agreement.

5.6.

Inventory

The Company’s inventory of dry cannabis and oil includes both purchased and internally produced inventory. The Company’s inventory is comprised of the following items:


	June 30, 2022		December 31, 2021		June 30, 2023		December 31, 2022
Raw materials	$	7,161	$	3,185	$	1,406	$	1,181
Finished goods		16,520		8,721		20,691		15,280
Work in process		27,842		26,852		26,891		26,406
Accessories, supplies and consumables		2,848		3,565		5,027		3,468
	$	54,371	$	42,323	$	54,015	$	46,335

The Company wrote down $1,081 of packaging inventory due primarily to defective cartridges during the six months ended June 30, 2023.

On February 4, 2022, more than 500 vape products were recalled by the Pennsylvania's Department of Health, including several of the Company's SKUs. As a result of the recall, the Company wrote off $1,071 and $1,925 of inventory during the three and six months ended June 30, 2022, respectively.

In addition, management wrote down its inventory by $6,351 and $6,570 for the three and six months ended June 30, 2022, ~~respectively, and $115~~ ~~and $699~~ ~~for the three and six months ended June 30, 2021.~~respectively. The inventory write-downs in the ~~current~~prior year period were mainly due to the write down of inventory to lower of cost or market which was related to the Company's ~~operational~~operations reconfiguration of its cultivation facility in Pennsylvania, as well as inventory in Canada that the Company deemed unsaleable. ~~The inventory write-downs in the prior year period were related to inventory that the Company deemed unsaleable.~~

6.7.

~~Property and equipment~~Discontinued operations

~~Property and equipment consisted of:~~

The Company determined to make available for sale the asset groups related to TerrAscend Canada's Licensed Producer business. Therefore, the results of operations have been reclassified as discontinued operations on a retrospective basis for all periods presented.

The major classes of assets and liabilities from discontinued operations included the following:

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

June 30, 2022

December 31, 2021

Land

$
7,613

$
4,183

Assets in process

52,624

6,858

Buildings & improvements

157,814

118,014

Machinery & equipment

27,906

23,424

Office furniture & equipment

8,290

3,232

Assets under finance leases

4,961

239

Total cost

259,208

155,950

Less: accumulated depreciation

(20,411
)

(15,188
)
Property and equipment, net

$
238,797

$
140,762


	June 30, 2023		December 31, 2022
Land		—	$	734
Buildings & improvements		—		16,529
Office furniture & equipment		—		86
Total assets held for sale		—	$	17,349

Prepaid expenses and other current assets		509		571
Current assets from discontinued operations	$	509	$	571

Accounts payable and accrued liabilities	$	1,466	$	3,747
Loans payable		—		5,364
Current liabilities from discontinued operations	$	1,466	$	9,111

The results of operations for the discontinued operations includes revenues and expenses directly attributable to the operations disposed. Corporate and administrative expenses, including interest expense, not directly attributable to the operations were not allocated to TerrAscend Canada's Licensed Producer business. The results of discontinued operations were as follows:


	For the Three Months Ended						For the Six Months Ended
	June 30, 2023			June 30, 2022			June 30, 2023			June 30, 2022

Revenue		—		$	1,146			—		$	2,531
Excise and cultivation tax		—			(302	)		—			(613	)
Revenue, net		—			844			—			1,918

Cost of Sales		—			1,802			—			3,360

Gross profit		—			(958	)		—			(1,442	)

Operating expenses:
General and administrative		455			1,056			756			2,184
Amortization and depreciation		—			435			48			878
Impairment of property and equipment		—			—			3,064			—
Total operating expenses		455			1,491			3,868			3,062

Loss from discontinued operations		(455	)		(2,449	)		(3,868	)		(4,504	)
Other expense
Finance and other expenses		166			248			344			449
Net loss from discontinued operations	$	(621	)	$	(2,697	)	$	(4,212	)	$	(4,953	)

Asset Specific Impairment

Certain assets of TerrAscend Canada were determined to be held for sale as they met the criteria under ASC 360 Property, Plant and Equipment. TerrAscend Canada operated out of a 67,300 square foot facility located in Mississauga, Ontario. Assets held for sale are reported at the lower of its carrying value or fair value less cost to sell. On May 23, 2023, the Mississauga, Ontario facility was sold for CAD $19,700 (U.S. $14,285). Net proceeds have been applied to pay down existing Company debt.

Property and equipment

Property and equipment consisted of:

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)


	June 30, 2023			December 31, 2022
Land	$	6,713		$	6,512
Assets in process		26,181			28,416
Buildings & improvements		159,356			154,742
Machinery & equipment		33,337			30,973
Office furniture & equipment		8,727			7,576
Assets under finance leases		2,530			7,277
Total cost		236,844			235,496
Less: accumulated depreciation		(27,849	)		(19,684	)
Property and equipment, net	$	208,995		$	215,812

Assets in process represent construction in progress related to both cultivation and dispensary facilities not yet completed, or otherwise not placed in service.

~~During the six months ended~~As of June 30, ~~2022~~2023 and ~~the twelve months ended~~ December 31, ~~2021,~~2022, borrowing costs were 0not capitalized because the assets in process did not meet the criteria of a qualifying asset.

Depreciation expense was $3,395 and $6,652 for the three and six months ended June 30, 2023, respectively ($2,023 and $4,040 included in cost of sales) and $3,027 and $~~5,513~~4,684 for the three and six months ended June 30, 2022, respectively ($1,670 and $~~3,406, respectively included in cost of sales) and $1,805~~ ~~and $3,771~~ ~~for the three and six months ended June 30, 2021, respectively ($1,127~~ ~~and $2,225~~3,171 included in cost of sales).

7.9.

Intangible assets and goodwill

Intangible assets consisted of the following:


At June 30, 2022	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
At June 30, 2023								Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite lived intangible assets
Software	$	2,926	$	(1,819	)	$	1,107	$	1,286	$	(817	)	$	469
Licenses		284,818		(17,301	)		267,517		208,384		(22,016	)		186,368
Brand intangibles		1,144		(568	)		576		1,144		(1,144	)		-
Non-compete agreements		280		(48	)		232		280		(280	)		-
Total finite lived intangible assets		289,168		(19,736	)		269,432		211,094		(24,257	)		186,837
Indefinite lived intangible assets
Brand intangibles		82,206		—			82,206		82,757		—			82,757
Total indefinite lived intangible assets		82,206		—			82,206		82,757		—			82,757
Intangible assets, net	$	371,374	$	(19,736	)	$	351,638	$	293,851	$	(24,257	)	$	269,594


At December 31, 2021	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
At December 31, 2022								Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite lived intangible assets
Software	$	2,626	$	(1,353	)	$	1,273	$	1,169	$	(569	)	$	600
Licenses		153,300		(11,311	)		141,989		178,929		(22,590	)		156,339
Brand intangibles		1,144		(254	)		890		1,144		(1,144	)		-
Non-compete agreements		280		(221	)		59		280		(272	)		8
Total finite lived intangible assets		157,350		(13,139	)		144,211		181,522		(24,575	)		156,947
Indefinite lived intangible assets
Brand intangibles		24,773		—			24,773		82,757		—			82,757
Total indefinite lived intangible assets		24,773		—			24,773		82,757		—			82,757
Intangible assets, net	$	182,123	$	(13,139	)	$	168,984	$	264,279	$	(24,575	)	$	239,704

1114

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

Amortization expense was $~~4,019~~1,595 and $~~6,618~~3,109 for the three and six months ended June 30, 2023, respectively ($725 and $1,450 included in cost of sales) and $3,871 and $6,333 for the three and six months ended June 30, 2022, respectively ($2,345 and $3,076~~, respectively included in cost of sales) and $1,787~~ ~~and $3,279~~ ~~for the three and six months ended June 30, 2021, respectively ($621~~ ~~and $1,108, respectively~~ included in cost of sales).

Estimated future amortization expense for finite lived intangible assets for the next five years is as follows:


2022	$	8,236
2023	$	15,661
Remainder of 2023			$	4,501
2024	$	15,234		8,662
2025	$	14,797		8,396
2026	$	14,748		8,381
2027				8,301

The Company's goodwill is allocated to one reportable segment. The following table summarizes the activity in the Company’s goodwill balance:

Balance at December 31, 2021

$
90,326

Acquisitions (see Note 4)

150,272

Balance at June 30, 2022

$
240,598

~~Impairment of Intangible Assets~~

For the Three Months Ended

For the Six Months Ended

June 30, 2022

June 30, 2021

June 30, 2022

June 30, 2021

Finite lived intangible assets

Software

$
-

$
9

$
-

$
9

Licenses

—

—

—

-

Customer Relationships

—

2,000

—

2,000

Non-compete agreements

—

224

—

224

Total impairment of finite lived intangible assets

—

2,233

—

2,233

Indefinite lived intangible assets

Brand intangibles

—

1,400

—

1,400

Total impairment of indefinite lived intangible assets

—

1,400

—

1,400

Total impairment of intangible assets

$
-

$
3,633

$
-

$
3,633


Balance at December 31, 2022	$	90,328
Acquisitions (see Note 5)		9,004
Measurement period adjustment		620
Balance at June 30, 2023	$	99,952

10.

Loans payable


	Ilera Term Loan			Stearns Loan			Gage Loans			Pinnacle Loans			Pelorus Term Loan			Maryland Acquisition Loans			Class A Share Gage Growth Corp		IHC Note Payable			Total
Balance at December 31, 2022	$	110,850		$	-		$	29,976		$	9,333		$	44,028		$	-		$	-	$	-		$	194,187
Loan principal, net of transaction costs					23,872			—			—			—			15,485			1,000		7,500			47,857
Loan amendment fee / Prepayment penalty		(2,328	)		—			—			—			—			—			—		—			(2,328	)
Interest and accretion		8,405			38			2,189			266			3,332			—			—		—			14,230
Principal and interest paid		(40,469	)		—			(3,132	)		(1,266	)		(3,251	)		—			—		(1,500	)		(49,618	)
Effects of movements in foreign exchange		—			—			—			—			—			—			—		—			-
Ending carrying amount at June 30, 2023		76,458			23,910			29,033			8,333			44,109			15,485			1,000		6,000			204,328
Less: current portion		(3,461	)		(405	)		(3,214	)		(8,333	)		(551	)		(1,964	)		—		(6,000	)		(23,928	)
Non-current loans payable	$	72,997		$	23,505		$	25,819			—		$	43,558		$	13,521		$	1,000	$	-		$	180,400

~~In August 2021, the Company made the decision to undertake a strategic review process to explore, review and evaluate potential alternatives for its Arise business focused~~Total interest paid on ~~maximizing shareholder value. As a result of this review, the Company recorded impairment of intangible assets of~~all loan payables was $~~3,633~~6,803 and $9,259 for the three and six months ended June 30, ~~2021.~~2023, respectively, and $6,370 and $14,406 for the three and six months ended June 30, 2022, respectively.

~~Loans payable~~

Canopy Growth (formerly RIV Capital) Loan

Canopy Growth- Canada Inc Loan

Other Loans

Canopy Growth- Arise Loan

Ilera Term Loan

KCR Loan

Gage loans

Total

Balance at December 31, 2021

$
8,680

$
42,165

$
7,915

$
8,900

$
115,233

$
2,250

$
-

$
185,143

Addition on acquisition

—

—

—

—

—

—

60,605

60,605

Loan amendment fee

—

—

—

—

(1,200
)

—

—

(1,200
)
Interest accretion

665

2,739

319

702

8,542

74

2,819

15,860

Principal and interest paid

(624
)

(3,837
)

(2,586
)

—

(7,662
)

(2,324
)

(2,811
)

(19,844
)
Effects of movements in foreign exchange

(142
)

(691
)

(94
)

—

—

—

—

(927
)
Ending carrying amount at June 30, 2022

$
8,579

$
40,376

$
5,554

$
9,602

$
114,913

$
-

$
60,613

$
239,637

Less: current portion

(309
)

(1,170
)

(464
)

—

(42
)

—

(56,871
)

(58,856
)
Non-current loans payable

$
8,270

$
39,206

$
5,090

$
9,602

$
114,871

$
-

$
3,742

$
180,781

Ilera Term Loan

12On April 14, 2023, WDB Holding PA agreed to an amendment to the Ilera Term Loan among other things, to (i) permit changes necessary for the TSX Transaction (as defined therein), and (ii) to waive certain tax provisions. On June 22, 2023, WDB Holding PA further agreed to an amendment among other things, to (i) extend the next test date for the interest coverage ratio from June 30, 2023 until September 30, 2023, and (ii) amend the terms for which WDB Holding PA may incur certain indebtedness and liens.

In accordance with ASC 470, Debt, the amendments above were not considered extinguishment of debt.

Stearns Loan

On June 26, 2023, the Company closed on a $25,000 commercial loan with Stearns Bank, secured by the Company's cultivation facility in Pennsylvania and its AMMD dispensary in Cumberland, Maryland ("Stearns Loan"). The loan carries an interest rate of prime plus 2.25% and matures on December 26, 2024. The Company is required to hold $2,500 on deposit in a restricted account.

Gage Loans

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

~~Total interest paid on all loan payables was $6,370~~ ~~and $14,641~~On June 9, 2023, TerrAscend Growth Corp. agreed to an amendment among other things, to (i) permit changes necessary for the ~~three~~TSX Transaction (as defined therein) and ~~six months ended June 30, 2022, respectively,~~(ii) to permit certain indebtedness and $~~4,150~~ ~~and $13,290~~ ~~for the three and six months ended June 30, 2021, respectively.~~waive certain tax provisions.

Pinnacle Loan

~~Gage loans~~

The ~~Gage~~Pinnacle Acquisition ~~(refer to Note 4)~~purchase price included ~~a senior secured term loan with~~two promissory notes in an ~~acquisition date fair value~~aggregate amount of $~~53,357~~10,000. to pay down all Pinnacle liabilities and encumbrances. The ~~Credit Agreement bears~~promissory notes carry an interest ~~at a rate equal to the greater of the Prime Rate plus~~ 7~~% or~~ ~~10.25%. The term loan is payable monthly and matures on~~ ~~November 30, 2022. The term loan is secured by a first lien on all Gage assets.~~

~~Additionally, the Gage Acquisition included a loan payable to a former owner of a licensed entity with an acquisition date fair value of $2,683, and a Promissory Note with an acquisition date fair value of $4,065. The loan payable to the former owner bears interest at a rate of~~ ~~0.2%. The Promissory Note bears interest at a fixed~~ rate of 6%. On June 27, 2023, Spartan Partners Properties, LLC agreed to an amendment among other things, to extend the obligation date of the loan until December 1, 2023.

In accordance with ASC 470, Debt, the amendments above were not considered extinguishment of debt.

Pelorus Term Loan

On April 17, 2023, TerrAscend NJ, LLC agreed to an amendment among other things, to (i) permit changes necessary for the TSX Transaction (as defined therein), and (ii) to waive certain tax provisions. On June 22, 2023, TerrAscend NJ, LLC further agreed to an amendment to permit certain indebtedness.

In accordance with ASC 470, Debt, the amendments above were not considered extinguishment of debt.

Maryland Acquisition Loans

On June 28, 2023, related to the acquisition of Peninsula, the Company assumed financing obligations in the amount of $7,698, which matures on June 28, 2025. The promissory note carries an interest rate of 8.25%. The Company will make monthly payments of principal and interest totaling $157 beginning on July 28, 2023. The Company is required to make a mandatory prepayment of 50% of the outstanding principal balance on January 28, 2025. The consideration also included a promissory note in the amount of $3,927. The promissory note carries an interest of 7.25% and is payable in twelve quarterly installments, maturing on June 28, 2026.

One June 30, 2023, related to the acquisition of Blue Ridge, the Company agreed to a promissory note in the amount of $3,750 payable in four quarterly installments of accrued interest commencing on September 30, 2023 and twelve equal quarterly installments of principal and accrued interest commencing on September 30, 2024. The remaining amount of the principal and accrued interest is due on June 30, 2027, the maturity date. The promissory note carries an interest rate of 7.0%.

Class A Share of TerrAscend Growth

As a part of the Reorganization (See Note 3), TerrAscend Growth Corp. issued $1,000 of Class A shares with a 20% guaranteed annual dividend. Under the Subscription Agreement, TerrAscend Growth Corp holds a call right to repurchase all of the Class A Shares, at any point in time, issuable to the holder of Class A Shares and the holder of Class A shares is granted a put right that is exercisable at any time following the five-year anniversary of the closing of the investment. The instrument is considered as a debt due to the economic characteristics and risks. The repurchase / put price is defined as the sum of: (a) the Repurchase/Put Price; plus (b) the amount equal to 40% of the Subscription Amount less the aggregate Dividend Amounts paid to the Subscriber as of the date of the Exercise Notice.

IHC Real Estate LP Loan

Maturities of loans payable

Stated maturities of loans payable over the next five years are as follows:

June 30, 2022

2022

$
56,589

2023

9,187

2024

131,869

2025

—

2026

—

Thereafter

82,491

Total principal payments

$
280,136

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)


	June 30, 2023
Remainder of 2023	$	13,845
2024		137,216
2025		8,466
2026		3,649
2027		43,219
Thereafter		2,264
Total principal payments	$	208,659

9.11.

Leases

The majority of the Company’s leases are operating leases used primarily for corporate offices, retail, cultivation and manufacturing. The operating lease periods generally range from 1 to 28 years. The Company had 3two and three finance leases at June 30, ~~2022~~2023 and1 ~~finance lease at~~ December 31, ~~2021.~~2022, respectively.

Amounts recognized in the consolidated balance sheet ~~are~~were as follows:


	June 30, 2022		December 31, 2021		June 30, 2023		December 31, 2022
Operating leases:
Operating lease right-of-use assets	$	30,570	$	29,561	$	32,824	$	29,451

Operating lease liability classified as current		1,394		1,171		1,911		1,857
Operating lease liability classified as non-current		31,680		30,573		35,207		31,545
Total operating lease liabilities	$	33,074	$	31,744	$	37,118	$	33,402

Finance leases:
Property and equipment, net	$	4,724	$	168	$	2,374	$	6,673

Lease obligations under finance leases classified as current		384		22		275		521
Lease obligations under finance leases classified as non-current		4,794		181		2,139		6,713
Total finance lease obligations	$	5,178	$	203	$	2,414	$	7,234

The Company recognized operating lease expense of $1,254 and $2,451 for the three and six months ended June 30, 2023, respectively. and 2022, respectively and $1,173 and $2,355 for the three and six months ended June 30, ~~2022, respectively and $~~2022.~~1,231~~

~~and $~~

~~2,109~~ ~~for the three and six months ended~~Other information related to operating leases at June 30, ~~2021, respectively.~~2023 and December 31, 2022 consisted of the following:


	June 30, 2023			December 31, 2022
Weighted-average remaining lease term (years)
Operating leases		12.9			12.8
Finance leases		0.7			6.8

Weighted-average discount rate
Operating leases		11.04	%		10.69	%
Finance leases		9.47	%		9.89	%

~~On January 27, 2022, the Company made a payment of $~~

~~3,300~~Supplemental cash flow information related to the Lease Termination at its Hagerstown location which enables the Company to terminate its building lease at a later date. The lease termination fee was expensed during the year ended December 31, 2021.leases are as follows:


	June 30, 2023		December 31, 2022
Cash paid for amounts included in measurement of operating lease liabilities	$	2,451	$	5,053
Right-of-use assets obtained in exchange for operating lease obligations		3,764		3,097
Cash paid for amounts included in measurement of finance lease liabilities		254		220
Assets under finance leases obtained in exchange for finance lease obligations		-		6,913

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

~~Other information related to operating leases at June 30, 2022 and December 31, 2021 consist of the following:~~

June 30, 2022

December 31, 2021

Weighted-average remaining lease term (years)

Operating leases

12.9

14.2

Finance leases

9.9

5.5

Weighted-average discount rate

Operating leases

10.69
%

10.72
%

~~Supplemental cash flow information related to leases are as follows:~~

June 30, 2022

December 31, 2021

Cash paid for amounts included in measurement of operating lease liabilities

$
2,434

$
3,987

Right-of-use assets obtained in exchange for lease obligations

$
6,641

$
9,773

Cash paid for amounts included in measurement of finance lease liabilities

$
67

$
40

Undiscounted lease obligations are as follows:

Operating

Finance

Total

2022

$
2,448

$
264

$
2,712

2023

4,975

824

5,799

2024

4,966

757

5,723

2025

4,950

775

5,725

2026

4,672

794

5,466

Thereafter

43,887

4,608

48,495

Total lease payments

65,898

8,022

73,920

Less: interest

(32,824
)

(2,844
)

(35,668
)
Total lease liabilities

$
33,074

$
5,178

$
38,252


	Operating			Finance			Total
Remainder of 2023		4,326			96		$	4,422
2024		6,054			2,130			8,184
2025		6,045			132			6,177
2026		5,570			134			5,704
2027		5,080			136			5,216
Thereafter		48,419			81			48,500
Total lease payments		75,494			2,709			78,203
Less: interest		(38,376	)		(295	)		(38,671	)
Total lease liabilities	$	37,118		$	2,414		$	39,532

Under the terms of these operating sublease agreements, future rental income from such third-party leases is expected to be as follows:



2022	$	243
2023		435
Remainder of 2023			$	313
2024		434		551
2025		448		445
2026		263		262
2027				—
Thereafter		-		—
Total rental payments	$	1,823	$	1,571

A sale-leaseback transaction occurs when an entity sells an asset it owns and then immediately leases the asset back from the buyer. The seller then becomes the lessee and the buyer becomes the lessor. Under ASC 842, Leases, both parties must assess whether the buyer-lessor has obtained control of the asset and a sale has occurred. ~~The Company's subsidiary~~Through the Gage Acquisition, the Company entered into leaseback transactions on 5six properties of owned real estate. The Company has determined that these transactions do not qualify as a sale because control was not transferred to the buyer-lessor. Therefore, the Company has classified the lease portion of the transaction as a finance lease and continues to depreciate the asset. The Gage ~~Acquisition (refer to Note 4)~~acquisition included financing obligations. The balance at June 30, ~~2022~~2023 was $~~12,352~~11,614. Of this amount, $~~746~~860 is included in other current liabilities and $~~11,606~~10,754 is included in financing obligations in the unaudited consolidated balance sheets. The financing obligations had a weighted average term and weighted average discount rate of 7.2 years and 9.6%, respectively, at June 30, 2023.

Undiscounted financing obligations as of June 30, 2023 are as follows:



Remainder of 2023		974
2024		1,940
2025		1,986
2026		2,032
2027		2,079
Thereafter		5,680
Total payments		14,691
Less: interest		(3,077	)
Total financing obligations	$	11,614

~~10.~~12.

~~Shareholders’ equity~~Convertible Debt

On June 23, 28, and 30, 2023, the Company closed the private placements of 10,105 senior unsecured convertible debentures at a price of $1,000 per debenture for total gross proceeds of $10,105. Unless repaid or converted earlier, the outstanding principal and accrued and unpaid interest on the debentures will be due and payable 36 months following the closing of the debenture Offering (the “Maturity Date”). Each debenture will bear interest at a rate of 9.9% per annum from the date of issuance, calculated and compounded semi-annually, and payable on the Maturity Date. Each holder may, at the option of the holder upon signing of the subscription agreement, elect to receive up to 4.95% per annum of such interest payable in cash on a semi-annual basis. Each debenture will be convertible into

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

common shares, at the option of the holder, at any time or times prior to the close of business on the last business day immediately preceding the Maturity Date, at a conversion price of $2.01. Holders converting their debentures will receive accrued and unpaid interest for the period from and including the date of the last interest payment date, to and including, the date of conversion.

In accordance with ASC 815 Derivatives and Hedging, the conversion option was bifurcated from the host instrument as the instrument's strike price is denominated in a currency other than the functional currency of the issuer. It was recorded at fair value, using the Black-Scholes option model (Note 23). The proceeds are allocated first to the conversion option based on its fair value of $3,533, and the residual was allocated to the host instrument and recorded as convertible debt at a fair value of $6,572.

13.

Shareholders' equity

Warrants

The following is a summary of the outstanding warrants for ~~Common Shares:~~common shares:

Number of Common Share Warrants Outstanding

Number of Common Share Warrants Exercisable

Weighted Average Exercise Price $

Weighted Average Remaining Life (years)

Outstanding, December 31, 2021

30,995,473

8,855,066

$
4.20

5.66

Exercised

(7,989,436
)

Replacement warrants granted on acquisition of Gage

282,023

Outstanding, June 30, 2022

23,288,060

1,110,168

$
4.71

7.06


	Number of Common Share Warrants Outstanding			Number of Common Share Warrants Exercisable			Weighted Average Exercise Price $		Weighted Average Remaining Life (years)
Outstanding, December 31, 2022		23,240,330			728,715		$	4.49		9.72
Expired		(320,000	)		(320,000	)		3.50		—
Outstanding, June 30, 2023		22,920,330			408,715		$	4.61		9.35

~~Pursuant to the terms of the Gage Acquisition, each holder of a Gage warrant received a~~ ~~0.3001~~ ~~equivalent replacement warrant. Each warrant is exercisable into common share purchase warrants. The warrants range in exercise price from $3.83~~ ~~to $7.00~~ ~~and expire at various dates from~~ ~~October 6, 2022~~ to ~~July 2, 2025. Refer to Note 4 for the determination of fair value of warrants acquired.~~

The Gage Acquisition also included warrant liabilities that are exchangeable into ~~Common Shares. Refer to Note 4 for the determination of the fair value of the warrant liability.~~common shares.

Number of Common Share Warrants Outstanding

Number of Common Share Warrants Exercisable

Weighted Average Exercise Price $

Weighted Average Remaining Life (years)

Outstanding, December 31, 2021

-

-

$
-

-

Granted on acquisition of Gage

7,129,517

Outstanding, June 30, 2022

7,129,517

7,129,517

$
8.66

1.49


	Number of Common Share Warrants Outstanding		Number of Common Share Warrants Exercisable		Weighted Average Exercise Price $		Weighted Average Remaining Life (years)
Outstanding, December 31, 2022		7,129,517		7,129,517	$	8.66		0.99
Granted		3,590,334		—	$	1.95		1.98
Exercised		—		—		—		—
Outstanding, June 30, 2023		10,719,851		7,129,517	$	6.41		0.99

The following is a summary of the outstanding ~~warrants for Proportionate Voting Shares at June 30, 2022. These warrants are exercisable for~~ ~~0.001~~ ~~of a Proportionate Voting Share. The Proportionate Voting Shares are exchangeable into Common Shares on a basis of~~ ~~1,000~~ ~~Common Shares per Proportionate Voting Share.~~

Number of Proportionate Share Warrants Outstanding

Number of Proportionate Share Warrants Exercisable

Weighted Average Exercise Price $

Weighted Average Remaining Life (years)

Outstanding, December 31, 2021

8,590,908

8,590,908

$
5.69

0.64

Exercised

—

Outstanding, June 30, 2022

8,590,908

8,590,908

$
5.60

0.15

~~The following is a summary of the outstanding Preferred Share~~preferred share warrants at June 30, ~~2022.~~2023. Each warrant is exercisable into 1one preferred share:

Number of Preferred Share Warrants Outstanding

Number of Preferred Share Warrants Exercisable

Weighted Average Exercise Price $

Weighted Average Remaining Life (years)

Outstanding, December 31, 2021

16,056

16,056

$
3,000

1.39

Exercised

(950
)

Outstanding, June 30, 2022

15,106

15,106

$
3,000

0.90


	Number of Preferred Share Warrants Outstanding			Number of Preferred Share Warrants Exercisable			Weighted Average Exercise Price $		Weighted Average Remaining Life (years)
Outstanding, December 31, 2022		15,106			15,106		$	3,000		0.39
Expired		(15,106	)		(15,106	)		3,000		—
Outstanding, June 30, 2023		-			-		$	-		-

Private Placement Financing

Concurrently with convertible debenture placements (Note 12), on June 23, 2023, June 28, 2023, and June 30, 2023, the Company closed three tranches of private placements of equity securities at a price of $1.50 per unit for aggregate gross proceeds of $9,871. Each unit is comprised of one common share of the Company and one-half warrant to purchase one common share. Each warrant entitles the holder to acquire one common share at a price of $1.95 per common share for a period of 24 months following the date of issuance.

~~11.~~

~~Share-based compensation plans~~

15Detachable warrants issued in a bundled transaction are accounted for separately. Under ASC 815 Derivatives and Hedging, the detachable warrants meet the definition of derivative because the exercise price is denominated in a currency that is different from the

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

functional currency of the Company. It was recorded at a fair value of $2,216, using the Black-Scholes option model. The proceeds are allocated first to the warrants based on their fair value, and the residual of $7,655 was allocated to the equity (Note 23).

14.

Share-based compensation plans

Share-based payments expense

Total share-based payments expense was as follows:



	For the Three Months Ended					For the Six Months Ended					For the Three Months Ended					For the Six Months Ended
		June 30, 2022		June 30, 2021			June 30, 2022		June 30, 2021			June 30, 2023		June 30, 2022			June 30, 2023		June 30, 2022
Stock options		$	3,500	$	4,316		$	6,090	$	7,766		$	1,437	$	3,500		$	2,697	$	6,090
Restricted share units			963		332			1,729		449		$	544	$	963			997		1,729
Total share-based payments		$	4,463	$	4,648		$	7,819	$	8,215		$	1,981	$	4,463		$	3,694	$	7,819

Stock Options

The following table summarizes the stock option activity for the six months ended June 30, ~~2022:~~2023:

Number of Stock Options

Weighted average remaining contractual life (in years)

Weighted Average Exercise Price (per share) $

Aggregate intrinsic value

Weighted average fair value of nonvested options (per share) $

Outstanding, December 31, 2021

12,854,519

4.84

$
4.85

$
27,557

$
4.22

Granted

4,182,590

5.16

Replacement options granted on acquisition of Gage

4,940,364

2.99

Exercised

(88,015
)

4.04

Forfeited (1)

(649,376
)

8.65

Expired

(396,441
)

8.08

Outstanding, June 30, 2022

20,843,641

4.94

$
4.24

3,615

$
-

Exercisable, June 30, 2022

12,396,267

3.07

$
3.11

3,615

N/A

Nonvested, June 30, 2022

8,447,374

7.69

$
5.89

-

N/A


	Number of Stock Options			Weighted average remaining contractual life (in years)		Weighted Average Exercise Price (per share) $		Aggregate intrinsic value		Weighted average fair value of nonvested options (per share) $
Outstanding, December 31, 2022		20,111,246			4.86	$	3.63	$	320	N/A
Granted		706,627			—		1.75		—		—
Exercised		(405,134	)		—		0.19		—		—
Forfeited		(1,386,353	)		—		5.38		—		—
Expired		(1,507,019	)		—		4.20		—		—
Outstanding, June 30, 2023		17,519,367			4.73	$	3.65		1,047		—

Exercisable, June 30, 2023		11,633,165			2.98	$	3.58		202		—

Nonvested, June 30, 2023		5,886,199			8.22	$	3.81	$	845		—

~~(1)~~

~~For stock options forfeited, represents one share for each stock option forfeited.~~

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between ~~the~~ Company’s closing stock price on June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively, and the exercise price, multiplied by the number of the in-the-money options) that would have been received by the option holders had ~~all option holders~~they exercised their in-the-money options on June 30, ~~2022~~2023 and December 31, ~~2021,~~2022, respectively.

The total pre-tax intrinsic value (the difference between the market price of the Company’s ~~Common Stock~~common shares on the exercise date and the price paid by the option holder to ~~the~~ exercise the option) related to stock options exercised is presented below:

For the Three Months Ended

For the Six Months Ended

June 30, 2022

June 30, 2021

June 30, 2022

June 30, 2021

Exercised

$
79

$
1,721

$
140

$
4,798


	For the Three Months Ended					For the Six Months Ended
		June 30, 2023		June 30, 2022			June 30, 2023		June 30, 2022
Exercised			—	$	79		$	551	$	140

~~The Gage Acquisition included consideration in the form of~~ ~~4,940,364~~ ~~replacement options that had been issued before the acquisition date to employees of Gage. The post-combination options vest over a 1-3 year~~ ~~period.~~ ~~The fair value of the replacement options are estimated using the Black-Scholes Option Pricing Model with the following assumptions:~~

1620

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)


	~~March 10, 2022~~
~~Volatility~~	~~55.0~~%-~~80.0~~%
~~Risk-free interest rate~~	~~1.22~~%-~~1.94~~%
~~Expected life (years)~~	~~1.00~~-~~5.00~~
~~Dividend yield~~		0	%

The fair value of the various stock options granted ~~was~~were estimated using the Black-Scholes ~~Option Pricing Model~~option pricing model with the following assumptions:


	June 30, 2022			December 31, 2021			June 30, 2023			December 31, 2022
Volatility	77.55% - 79.04%			79.05% - 81.51%			80.04% - 80.16%			77.55% - 77.89%
Risk-free interest rate	1.63% - 3.02%			0.90% - 1.72%			2.85% - 3.21%			1.63% - 3.51%
Expected life (years)	9.62 - 10.01			4.57 - 10.05			10.01			9.62 - 10.01
Dividend yield		0	%		0	%		0.00	%		0.00	%
Forfeiture rate		23.73	%	23.21% - 27.73%				26.11	%		26.11	%

Volatility was estimated by using the historical volatility of the Company's stock price. The expected life in years represents the period of time that the options issued are expected to be outstanding. The risk-free rate is based on USU.S. treasury bond issues with a remaining term approximately equal to the expected life of the options. Dividend yield is ~~zero since~~based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future.

The total estimated fair value of stock options that vested during the six months ended June 30, ~~2022~~2023 and ~~2021~~2022 was $~~4,921~~5,563 and $9,140, respectively. As of June 30, ~~2022,~~2023, there was $~~30,806~~23,572 of total unrecognized compensation cost related to unvested options.

Restricted Share Units

The following table summarizes the activities for the ~~unvested~~ RSUs for the three and six months ended June 30, ~~2022:~~2023:


	Number of RSUs			Number of RSUs vested		Weighted average remaining contractual life (in years)	Number of RSUs			Number of RSUs vested		Weighted average remaining contractual life (in years)
Outstanding, December 31, 2021		192,171			13,294	N/A
Outstanding, December 31, 2022								415,640			13,050	N/A
Granted		573,716						1,785,092			—		—
Vested		(58,825	)					(113,640	)		—		—
Forfeited		(23,250	)					(78,634	)		—		—
Outstanding, June 30, 2022		683,812			13,050	N/A
Outstanding, June 30, 2023								2,008,458			14,564	N/A

As of June 30, ~~2022,~~2023, there was $~~3,916~~3,129 of total unrecognized compensation cost related to unvested RSUs.

~~12.~~15.

Non-controlling interest

Non-controlling interest consists mainly of the Company’s ownership minority interest in its New Jersey ~~operations and~~operations.

On June 26, 2023, the Company reduced its non-controlling interest through a buy out of the minority interest in IHC Real Estate ~~operations and consists~~LP (Note 10).

The following table summarizes the non-controlling interest activity for the six months ended June 30, 2023:


	June 30, 2023			December 31, 2022
Opening carrying amount	$	2,374		$	5,367
Capital distributions		(3,415	)		(7,550	)
Transfer of minority interest		(1,323	)		-
Net income attributable to non-controlling interest		4,330			4,557
Ending carrying amount	$	1,966		$	2,374

This transaction was accounted for as an equity transaction. The carrying amount of the ~~following amounts:~~non-controlling interest was adjusted by $1,323 to reflect the change in the net book value ownership interest. The difference from the consideration paid of $7,500 is recognized in additional paid in capital and attributed to the parent’s equity holders.

June 30, 2022

December 31, 2021

Opening carrying amount

$
5,367

$
3,802

Capital distributions

(448
)

(53
)
Investment in NJ partnership

—

(1,406
)
Net income attributable to non-controlling interest

1,296

3,024

Ending carrying amount

$
6,215

$
5,367

~~13.~~16.

Related parties

1721

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

Parties are related if one party has the ability to control or exercise significant influence over the other party in making financing and operating decisions. At June 30, ~~2022~~2023 amounts due to/from related parties consisted of:

•(a)

Loans ~~payable:~~payable: During the year ended December 31, 2020, a small number of related persons, which consisted of key management of the Company, participated in the Ilera term loan (Note 8)9), which makes up $~~3,550~~163 of the total loan principal balance at June 30, ~~2022~~2023 and December 31, ~~2021, respectively.~~2022.

•(b)

~~Shareholders’ Equity: During~~Private Placement: The Private Placement constitutes a related party transaction because related persons, which consisted of key management and directors of the Company participated in the transaction. The Company’s Executive Chairman, participated, directly and indirectly, in the equity offering and acquired 800,002 Units for gross proceeds of $1,200. In total, the related persons acquired, in the aggregate, 2,000 Debentures and 825,734 Units in connection with the Private Placements for aggregate gross proceeds of $3,239.

17.

Income taxes

The Company's effective tax rate was (101%) and (148%) for the three and six months ended June 30, ~~2022, the Company had the following transactions related to shareholders’ equity:~~

•

~~Pursuant to the Gage Acquisition, Jason Wild~~2023, respectively and ~~his respective affiliates received~~ ~~10,467,229~~ ~~of the Company's Common Shares in exchange for their Gage subordinate voting shares that were owned, held, controlled or directed, directly or indirectly, by Mr. Wild and his respective affiliates and~~ ~~7,129,517~~ of the Company's warrants in exchange for their Gage warrants that were owned, held, controlled or directed, directly or indirectly, by Mr. Wild and his respective affiliates. The value of the interests of funds controlled directly or indirectly by Mr. Wild in the transaction in respect of the common shares was $~~52,335, in addition to the Company warrants issued in replacement of Gage warrants, at the implied consideration of $1.50~~ ~~per Gage warrant. Richard Mavrinac, a former director of the Company, received~~ ~~40,213~~ ~~Common Shares in exchange for his Gage subordinate voting shares that were owned, held, controlled or directed, directly or indirectly, by Mr. Mavrinac and also received~~ ~~6,683~~ Common Shares in exchange for his Gage restricted stock units that were owned, held, controlled or directed, directly or indirectly by Mr. Mavrinac. The value of Mr. Mavrinac's interest in the transaction was $~~234~~.

~~14.~~

~~Income taxes~~

~~The effective tax rate was~~ 25% and 128% for the three and six months ended June 30, 2022, ~~respectively and -~~31~~% and -~~60%respectively. The effective tax rate for the three and six months ended June 30, ~~2021, respectively.~~2023 differed from the federal statutory tax rate primarily due to the disallowed tax deductions for business expenses pursuant to Section 280E of the Internal Revenue Code of 1986, as amended (the "Code"), and a return to provision adjustment primarily related to the Company's New Jersey tax return filings. The effective tax rate for the three and six months ended June 30, 2022 differed from the federal statutory tax rate primarily due to the disallowed tax deductions for business expenses pursuant to Section 280E of the Code.

~~Unrecognized~~The Company's effective tax ~~benefits~~rate can vary each reporting period depending on, among other factors, the ~~Unaudited Interim Condensed Consolidated Balance Sheets of $9,318~~ ~~were reclassed from corporate income tax payable to other long term liability at December 31, 2021 as the classification better aligns with the recognition~~geographic and business mix of the ~~benefits.~~Company's earnings, changes to the valuation allowance, and permanently non-deductible expenses. Certain of these and other factors, including the Company's history and projections of pre-tax earnings, are considered in assessing the Company's ability to realize any deferred tax assets including net operating losses.

~~15.~~18.

General and administrative expenses

The Company’s general and administrative expenses were as follows:


	For the Three Months Ended					For the Six Months Ended					For the Three Months Ended					For the Six Months Ended
		June 30, 2022		June 30, 2021			June 30, 2022		June 30, 2021			June 30, 2023		June 30, 2022			June 30, 2023		June 30, 2022
Office and general		$	6,042	$	3,369		$	9,608	$	7,224		$	3,801	$	5,821			7,805		9,101
Professional fees			3,564		3,070			6,492		5,749			5,103		3,373			8,476		6,093
Lease expense			1,105		1,109			2,355		2,109			1,294		1,099			2,538		2,345
Facility and maintenance			813		597			1,450		1,315			1,364		813			2,608		1,450
Salaries and wages			13,629		7,451			22,917		15,102			14,334		13,147			27,830		21,945
Share-based compensation			4,463		4,648			7,819		8,215			1,981		4,463			3,694		7,819
Sales and marketing			4,365		506			5,892		1,428			2,599		4,209			5,255		5,596
Total		$	33,981	$	20,750		$	56,533	$	41,142		$	30,476	$	32,925		$	58,206	$	54,349

~~16.~~19.

Revenue, net

The Company’s disaggregated net revenue by source, primarily due to the Company’s contracts with its external customers ~~were~~was as follows:


	For the Three Months Ended					For the Six Months Ended
		June 30, 2022		June 30, 2021			June 30, 2022		June 30, 2021		For the Three Months Ended					For the Six Months Ended
												June 30, 2023		June 30, 2022			June 30, 2023		June 30, 2022
Retail												$	58,254	$	47,979		$	113,676	$	73,697
Wholesale		$	16,825	$	36,330		$	40,766	$	74,714			13,870		15,981			27,846		38,848
Retail			47,979		22,393			73,697		37,363
Total		$	64,804	$	58,723		$	114,463	$	112,077		$	72,124	$	63,960		$	141,522	$	112,545

1822

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

For the ~~three and~~ six months ended June 30, ~~2022~~2023 and ~~2021~~2022, the Company did 0not have any single customer that accounted for 10% or more of the Company’s revenue.

As a result of the vape recall in Pennsylvania (refer to ~~note~~Note 5), the Company recorded sales returns of ~~$nil and~~ $1,040 during the ~~three and~~ six months ended June 30, ~~2022, respectively.~~2022.

~~17.~~20.

Finance and other expenses

The Company’s finance and other expenses included the following:

For the Three Months Ended

For the Six Months Ended

June 30, 2022

June 30, 2021

June 30, 2022

June 30, 2021

Interest accretion

$
8,758

$
6,464

$
15,860

$
12,746

Forgiveness of principal and interest on loans

—

766

—

-

Indemnification asset release

3,998

2,599

3,973

3,796

Loss on disposal of fixed assets

845

37

929

37

Other expense (income)

301

(947
)

(4
)

(1,270
)
Total

$
13,902

$
8,919

$
20,758

$
15,309




	For the Three Months Ended					For the Six Months Ended
		June 30, 2023		June 30, 2022			June 30, 2023		June 30, 2022
Interest and accretion		$	7,965	$	8,515		$	15,840	$	15,412
Indemnification asset release			—		3,998			—		3,973
Employee retention credits transfer with recourse			—		—			2,235		—
Other (income) expense			206		1,150			183		933
Total		$	8,171	$	13,663		$	18,258	$	20,318

~~The indemnification asset release is the reduction of the indemnification asset related~~Refer to ~~the expiration of the escrow agreement related to the acquisition of The Apothecarium.~~Note 4, for further explanation about employee retention credits transfer with recourse.

~~18.~~21.

Segment information

Operating Segment

The Company determines its operating segments according to how the business activities are managed and evaluated by the Company’s chief operating decision maker. The Company operates under 1one operating segment, being the cultivation, production and sale of cannabis products.

Geography

The Company ~~operates with~~has subsidiaries located in Canada and the ~~US.~~

~~The Company had~~United States. For each of the ~~following~~six months ended June 30, 2023 and 2022, net revenue ~~by geography of:~~was primarily generated from sales in the United States. As a result of the Reorganization (Note 3) the Company consolidates its retail location in Canada and generated net revenue of $290 for the three months and six months ended June 30, 2023.

For the Three Months Ended

For the Six Months Ended

June 30, 2022

June 30, 2021

June 30, 2022

June 30, 2021

United States

$
63,952

$
52,457

$
112,545

$
102,141

Canada

852

6,266

1,918

9,936

Total

$
64,804

$
58,723

$
114,463

$
112,077

The Company had non-current assets by geography of:


	June 30, 2022		December 31, 2021		June 30, 2023		December 31, 2022
United States	$	842,569	$	409,150	$	614,277	$	577,750
Canada		28,730		29,563		842		1,844
Total	$	871,299	$	438,713	$	615,119	$	579,594

~~19.~~22.

Capital management

~~TerrAscend Corp.~~

~~Notes to the Unaudited Condensed Consolidated Financial Statements~~

~~(Amounts expressed in thousands of United States dollars, except for per share amounts)~~

The Company’s objective in managing capital is to ensure a sufficient liquidity position to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders. In order to achieve this objective, the Company prepares a capital budget to manage its capital structure. The Company defines capital as borrowings, equity comprised of issued share capital, share-based payments, accumulated deficit, as well as funds borrowed from related parties.

Since inception, the Company has primarily financed its liquidity needs through the issuance of share capital ~~through borrowings.~~and debt. The equity issuances are outlined in Note ~~11 and~~13, debt ~~issuances~~modification are outlined in Note 8.10, and debt financing are outline in Note 12.

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

The Company is subject to financial covenants as a result of its loans payable with various lenders. The Company is in compliance with its debt covenants as of June 30, ~~2022. Other than these items related to loans payable as of June 30, 2022 and December 31, 2021, the Company is not subject to externally imposed capital requirements.~~2023.

~~On April 28, 2022, the Ilera term loan (refer to Note 8) was amended to provide the Company with greater flexibility, and the optional prepayment date was amended to~~ ~~30 months~~ ~~(from~~ ~~18 months) from the closing date, subject to a premium payment due.~~

~~On August 10, 2022, the Gage senior secured term loan (refer to Note 8) was amended as~~As a result of the ~~corporate restructure in conjunction~~Reorganization, the Company has agreed to implement certain equity and capital management restrictions to comply with the ~~Gage Acquisition. The amendments~~rules and policies of the TSX. As such, the Company has agreed to limitations on the utilization of any proceeds raised through the sale of Company equity, including restrictions on funding of its US operations with such proceeds.

Additionally, the Company is prohibited from converting the exchangeable shares of TerrAscend Growth Corp. into common shares so long as the common shares are listed on the TSX or until the exchange of shares is permitted by TSX rules and policies. Until such time that the Company is permitted to convert its exchangeable shares for common shares, TerrAscend Growth Corp. may not issue dividends to the ~~Gage senior secured term loan include the addition of a borrower and guarantor under the term loan and a right of first offer in favor of the administrative agent for a refinancing of the term loan.~~Company.

~~20.~~23.

Financial instruments and risk management

Assets and liabilities measured at fair value

Cash and cash equivalents, net accounts receivable, accounts payable and accrued liabilities, loans payable, convertible debentures, and other current receivables and payables represent financial instruments for which the carrying amount approximates fair value due to their short-term maturities.

The following table represents the fair value amounts of financial assets and financial liabilities measured at estimated fair value on a recurring basis:


	At June 30, 2022								At December 31, 2021								At June 30, 2023							At December 31, 2022
		Level 1		Level 2			Level 3			Level 1		Level 2			Level 3			Level 1		Level 2		Level 3			Level 1		Level 2		Level 3
Assets
Cash and cash equivalents		$	48,426	$	-	—	$	-		$	79,642	$	-	—	$	-		$	28,915		—		—		$	26,158		—		—
Restricted cash			605		—			—			—		—			—			5,606		—		—			605		—		—
Purchase option derivative asset			—		—			50			—		—			868			—		—		—			—		—		50
Total Assets		$	49,031	$	-		$	50		$	79,642	$	-		$	868		$	34,521		—		—		$	26,763		—	$	50
Liabilities
Contingent consideration payable			—	$	-		$	5,648		$	-	$	-		$	12,535			—	$	4,434		—			—	$	5,184		—
Warrant liability			—		6,176			—			—		54,986			—
Derivative liability																			—		5,750		—			—		711		—
Total Liabilities		$	-	$	6,176		$	5,648		$	-	$	54,986		$	12,535			—	$	10,184		—			—	$	5,895		—

There were 0no transfers between the levels of fair value hierarchy during the three and six months ended June 30, ~~2022.~~2023.

The valuation approaches and key inputs for each category of assets or liabilities that are classified within levels of the fair value hierarchy are presented below:

Level 1

Cash, ~~and~~ cash equivalents, and restricted cash, net accounts receivable, accounts payable and accrued liabilities, loans payable, convertible debentures, and other current receivables and payables represent financial instruments for which the carrying amount approximates fair value due to their short-term maturities.

Level 2

~~Warrant liability~~

The following table summarizes the changes in the ~~warrant~~derivative liability for the three and six months ended June 30, ~~2022:~~2023:


Balance at December 31, 2022	$	711
Included in gain on fair value of warrants		(703	)
Conversion Option issued in 2023 private placement		3,533
Detachable warrants issued in 2023 private placement		2,216
Effects of movements in foreign exchange		(7	)
Balance at June 30, 2023	$	5,750

Warrant liability and conversion option

2024

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

Balance at December 31, 2021

$
54,986

Addition on acquisition

6,756

Included in gain on fair value of warrants

(53,876
)
Exercises

(1,690
)
Balance at June 30, 2022

$
6,176

The Company's warrant liability consists of the warrant liability acquired through its Gage Acquisition ("Gage Warrant Liability"), a detachable warrant liability issued through the private placement (Note 13), and a conversion option related to the convertible debenture offering (Note 12). Series A, B, C, and D convertible preferred stock issued through its 2020 private placements ~~("private placement warrant liability"), as well as the warrant liability acquired through its Gage Acquisition ("Gage warrant liability") (refer to Note 4).~~

~~The private placement warrant liability has been measured at fair value at June 30, 2022. Key inputs and assumptions used in the Black Scholes valuation were as follows:~~

June 30, 2022

December 31, 2021

Common Stock Price of TerrAscend Corp.

$
2.28

$
6.11

Warrant exercise price

$
3,000

$
3,000

Warrant conversion ratio

$
1,000

$
1,000

Annual volatility

65.7
%

65.5
%
Annual risk-free rate

2.9
%

0.6
%
Expected term (in years)

0.9

1.4

~~The Gage warrant liability has been remeasured at fair value at June 30, 2022. Key inputs and assumptions used in the Black Scholes valuation were as follows:~~

June 30, 2022

March 10, 2022

Common Stock Price of TerrAscend Corp.

$
2.28

$
5.70

Warrant exercise price

$
8.66

$
8.66

Annual volatility

62.88% - 63.73%

61.65% - 61.87%

Annual risk-free rate

2.9
%

1.8
%
Expected term (in years)

1.5

1.7

~~Level 3~~

~~Purchase option derivative asset~~

~~The following table summarizes the changes in the purchase option derivative asset:~~

Balance at December 31, 2021

$
868

Revaluation of purchase option derivative asset

(818
)
Balance at June 30, 2022

$
50

The purchase option derivative asset has been measured at fair value at the transaction date using the Monte Carlo simulation model that relies on assumptions around the Company's EBITDA volatility and risk adjusted discount, among others. Key inputs and assumptions used in the Monte Carlo simulation model are summarized below:

June 30, 2022

December 31, 2021

Term (in years)

0.8

1.3

Risk-free rate

2.5
%

0.4
%
EBITDA discount rate

15.5
%

15.0
%
EBITDA volatility

37.1
%

44.0
%

~~Contingent Consideration Payable~~

~~TerrAscend Corp.~~

~~Notes to the Unaudited Condensed Consolidated Financial Statements~~

~~(Amounts expressed in thousands of United States dollars, except for per share amounts)~~

The fair value of contingent consideration at June 30, 2022 and December 31, 2021 was determined using a probability weighted model based on the likelihood of achieving certain revenue and EBITDA scenario outcomes. A discount rate of ~~12.2% (June 30, 2021 –~~ ~~12.8%) was utilized to determine the present value of the liabilities, resulting in a loss on revaluation of contingent consideration of $~~34 ~~and $153~~ ~~for~~have expired during the three and six months ended June 30, ~~2022, respectively (June 30, 2021 - ($~~2023.7

)

The Gage Warrant Liability has been remeasured to fair value. Key inputs and $assumptions used in the Black-Scholes model were as follows:

~~2,990~~


	June 30, 2023			December 31, 2022
Common Stock Price of TerrAscend Corp.	$	1.52		$	1.13
Warrant exercise price	$	8.66		$	8.66
Annual volatility		56.3	%	97.1%-98.4%
Annual risk-free rate		5.5	%		4.8	%
Expected term (in years)		0.5			1.0

~~, respectively).~~

Detachable Warrants

The fair value of the detachable warrants as a part of June 2023 private placement (Note 13) was estimated using the Black-Scholes option pricing model with the following assumptions:


	June 30, 2023
Common Stock Price of TerrAscend Corp.	$1.65-$1.81
Option exercise price	$	1.95
Annual volatility	71.0%-71.1%
Annual risk-free rate	4.58%-4.66%
Expected term (in years)	1.98-2.00

Bifurcated conversion options

The ~~illustrative variance~~conversion option issued as a part of the ~~total contingent consideration~~June 2023 private placement (Note 12) has been measured at fair value as of June 30, ~~2022 based on reasonably possible changes to one of~~2023. Key inputs and assumptions used in the ~~significant unobservable inputs, holding other inputs constant, would have the following effects:~~Black-Scholes valuation were as follows:

Discount rate sensitivity

KCR

Increase 100 basis points

$
1,175

Increase 50 basis points

$
1,195

Decrease 50 basis points

$
1,236

Decrease 100 basis points

$
1,258


	June 30, 2023
Common Stock Price of TerrAscend Corp.	$1.65-$1.81
Option exercise price	$	2.01
Annual volatility	68.2%-68.3%
Annual risk-free rate	4.13%-4.25%
Expected term (in years)	2.98-3.00

~~21.~~24.

Commitments and contingencies

In the ordinary course of business, the Company is involved in a number of lawsuits incidental to its business, including litigation related to intellectual property, ~~product liability,~~ employment, and commercial matters. Although it is difficult to predict the ultimate outcome of these cases, management believes that any ultimate liability would not have a material adverse effect on the Company's consolidated balance sheets or results of operations. At June 30, ~~2022,~~2023, there were no pending lawsuits that could reasonably be expected to have a material effect on the results of the Company’s consolidated financial statements.

2225

TerrAscend Corp.

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

(Amounts expressed in thousands of United States dollars, except for share and per share amounts)

~~22.~~25.

Subsequent events

~~Subsequent to June 30, 2022,~~On July 4, 2023, the Company ~~opened The Apothecarium Lodi,~~commenced trading of its ~~third retail location in New Jersey and 27th dispensary overall. The retail location~~common shares on TSX under the new ticker symbol “TSND”. Subsequently, the ticker symbol on the OTC market was ~~opened on~~also changed to “TSNDF” effective July ~~25, 2022 to medical patients.~~ 6, 2023.

On July ~~26, 2022,~~10, 2023, the Company ~~received approval for Adult Use sales at this location.~~

acquired Herbiculture Inc. (“Herbiculture”) a dispensary in Maryland.

~~ii)~~

On July ~~27, 2022,~~28, 2023, subsequent to closing of the ~~Company's first "Cookies Corner" opened in its Maplewood dispensary in New Jersey.~~

Stearns Loan, the Company met the criteria for $2,500 of $5,000 of restricted cash to be released.

2326

~~Item~~ITEM 2. ~~Management's Discussion and Analysis of Financial Condition and Results of Operations~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of ~~the Company's~~TerrAscend's financial condition and results of operations should be read in conjunction with ~~the Company's~~TerrAscend's unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial information and the notes thereto included in the ~~Company's~~Company’s Annual Report on Form 10-K for the year ended December 31, ~~2021,~~2022, which was filed with the Securities and Exchange Commission, or SEC, on March ~~17, 2022.~~16, 2023, or the Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q including information with respect to ~~the Company's~~TerrAscend's plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth under "Risk Factors" in ~~the Company's~~our Annual Report, ~~on Form 10-K,~~ its actual results could differ materially from the results described in or implied by the "Cautionary Note Regarding Forward-Looking Statements" contained in this Quarterly Report on Form 10-Q and in the following discussion and analysis.

Unless otherwise noted, dollar amounts in this Item 2 are in thousands of U.S. dollars.

This Management’s Discussion and Analysis (“MD&A”) of the financial condition and results of operations of TerrAscend is for the three and six months ended June 30, ~~2022~~2023 and ~~2021~~2022 and the accompanying notes for each respective period.

~~Business~~ Overview

TerrAscend is a leading North American cannabis operator with vertically integrated licensed operations in Pennsylvania, New Jersey, Michigan, Maryland and California, ~~licensed cultivation~~ and ~~processing operations~~is a cannabis retailer in ~~Michigan and Maryland, and licensed processing operations~~Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada. ~~TerrAscend operates a chain of Apothecarium dispensary retail locations, as well as scaled cultivation, processing, and manufacturing facilities on both the east and west coasts of the United States.~~ TerrAscend’s cultivation and manufacturing practices yield consistent and high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use ~~market.~~markets. Notwithstanding the fact that various states in the ~~US which~~U.S. have implemented medical marijuana laws or ~~which~~that have otherwise legalized the use of cannabis, the use of cannabis remains illegal under USU.S. federal law for any purpose, by way of the ~~CSA.~~Controlled Substances Act of 1970.

TerrAscend operates under one operating segment, which is the cultivation, production and sale of cannabis products.

~~TerrAscend’s~~TerrAscend owns a portfolio of operating businesses and several synergistic brands ~~include:~~including:

●•

Allegany Medical Marijuana Dispensary ("AMMD"), a dispensary in Cumberland, Maryland;

•

Blue Ridge Wellness (“Blue Ridge”), a dispensary located in Parkville, Maryland;

•

Gage Growth ~~Corp.~~ ("Gage"), a vertically integrated cannabis cultivator, processor and ~~processor~~dispensary operator in ~~Michigan~~Michigan;

●•

Herbiculture Inc ("Herbiculture"), a dispensary located in Burtonsville, Maryland;

•

HMS Health, LLC (“HMS Health”) and HMS Processing, LLC (“HMS Processing” and together with HMS Health, “HMS”), a producer and seller of dried flower and oil products for the wholesale cannabis market in Maryland;

•

Ilera Healthcare ("Ilera"), a vertically integrated cannabis cultivator, processor and dispensary operator in Pennsylvania;

●•

~~TerrAscend NJ~~KISA Enterprises MI, LLC and KISA Holdings, LLC (collectively "Pinnacle"), a ~~majority owned subsidiary that holds a permit to operate up to three alternative treatment centers~~dispensary operator in ~~New Jersey with the ability to cultivate and process;~~Michigan;

●•

~~The Apothecarium, consisting of retail dispensaries~~Peninsula Alternative Health ("Peninsula"), a dispensary located in ~~California, Pennsylvania and New Jersey;~~Salisbury, Maryland;

●

~~Valhalla Confections, a provider of premium edible products;~~

●•

State Flower, a California-based cannabis producer operating a licensed cultivation facility in San Francisco, California;

●

~~HMS Health, LLC and HMS Processing, LLC, a producer and seller of dried flower and oil products for the wholesale medical cannabis market in Maryland;~~

●•

TerrAscend Canada ~~Inc.,~~(“TerrAscend Canada” or “TCI”) is a cannabis retailer in Ontario, Canada with a majority-owned dispensary in Toronto, Ontario, Canada ("Cookies Canada"). TerrAscend Canada was previously a Licensed Producer (as such term is defined in the Cannabis Act) of cannabis ~~with~~until TerrAscend commenced an optimization of its ~~current principal business activities including processing and sale of cannabis flower and oil products~~operations in ~~Canada;~~

●

Canada, whereby TerrAscend reduced its manufacturing footprint in order to focus on its Cookies Canada ~~the operator of a minority owned~~ retail ~~cannabis dispensary~~business, as well as monetize its intellectual property portfolio in ~~Toronto, Canada; and~~

●

~~Arise Bioscience, a manufacturer and distributor of hemp-derived products, located in Boca Raton, Florida.~~

~~Objective~~

~~TerrAscend's MD&A is designed to provide information about~~Canada. TerrAscend ceased operations at its financial condition and results of operations from management's perspective. It includes relevant components of TerrAscend's financial condition and current and long-term liquidity. Primary revenue drivers include the manufacture, distribution, and sale of medical and adult-use cannabis products where permitted. TerrAscend's primary obligations are related to compliance with state and federal regulators, as applicable. TerrAscend's primary sources of capital have been through the issuance of equity securities or debt. TerrAscend's objective is to discuss how all these factors have affected our historical results and, where applicable, how it expects these factors to impact its future results and future liquidity.

~~Results from Operations- Three months ended June 30, 2022 and June 30, 2021~~

~~The following tables represent the Company’s results from operations for the three months ended June 30, 2022 and 2021.~~

~~Revenue, net~~

For the Three Months Ended

June 30, 2022

June 30, 2021

Revenue

$
65,367

$
61,977

Excise and cultivation taxes

(563
)

(3,254
)
Revenue, net

$
64,804

$
58,723

$ change

$
6,081

% change

10
%

The increase in net revenue at June 30, 2022 as compared to June 30, 2021 was due to an increase in retail revenue of $25,586 from $22,393 for the three months ended June 30, 2021 to $47,979 for the three months ended June 30, 2022. The increase in revenue is mainly due to adult use sales in New Jersey which commencedmanufacturing facility during the three months ended December 31, 2022 and increased its ownership interest in Cookies Retail Canada Corp. to 95% of the issued and outstanding shares effective April 14, 2023;

•

TerrAscend NJ, LLC (“TerrAscend NJ”), a majority owned subsidiary that operates three dispensaries in New Jersey with the ability to cultivate and process;

•

The Apothecarium, consisting of retail dispensaries in California, Pennsylvania, and New Jersey;

•

Valhalla Confections, a provider of premium edible products.

TerrAscend’s head office and registered office is located at 77 City Centre Drive, Suite 501 – East Tower, Mississauga, Ontario, Canada, L5B 1M5.

TerrAscend’s telephone number is 1.717.610.4165 and its website is www.terrascend.com. Information contained on or accessible through TerrAscend’s website is not a part of this Quarterly Report, and the inclusion of TerrAscend’s website address in this Quarterly Report on Form 10-Q is an inactive textual reference only.

Recent Developments

•

On May 23, 2023, the Company completed the sale of its facility located in Mississauga, Canada for CAD $19,700 with net proceeds used to pay down existing Company debt.

•

On June 23, 28, and 30, 2023, the Company closed the private placements of 10,105 senior unsecured convertible debenture at a price of $1,000 per debenture for total gross proceeds of approximately $10,105. Unless repaid or converted earlier, the outstanding principal and accrued and unpaid interest on the debentures will be due and payable on the Maturity Date. Each debenture will bear interest at a rate of 9.9% per annum from the date of issuance, calculated and compounded semi-annually, and payable on the Maturity Date. Each holder may, at the option of the holder upon signing of the subscription agreement, elect to receive up to 4.95% per annum of such interest payable in cash on a semi-annual basis. Each debenture will be convertible into Common Shares, at the option of the holder, at any time or times prior to the close of business on the last business day immediately preceding the Maturity Date, at a conversion price of $2.01. Holders converting their debentures will receive accrued and unpaid interest for the period from and including the date of the last interest payment date, to and including, the date of conversion.

•

On June 26, 2023, the Company closed on the Stearns Loan, a $25,000 million commercial loan with Stearns Bank, secured by the Company’s cultivation facility in Pennsylvania and its AMMD dispensary in Cumberland, Maryland. The loan carries an interest rate of prime plus 2.25% and matures on December 26, 2024. The Company is required to hold $2,500 on deposit in a restricted account. The proceeds from the loan were used to pay down the Company's higher interest rate Ilera Term Loan, thereby lowering its overall interest expense.

•

On June 28, 2023, the Company completed the acquisition of Derby 1, LLC (d/b/a “Peninsula Alternative Health”), a dispensary in Maryland.

•

On June 29, 2023, the Company announced that its common shares would commence trading on the TSX on July 4, 2023 under the new ticker symbol “TSND”.

•

On June 30, ~~2022,~~2023, WDB Holding PA, Inc., a subsidiary of the Company, completed the paydown of $37,000 of its senior secured term loan in Pennsylvania.

•

On June 30, 2023, the Company completed the acquisition of Hempaid, LLC (d/b/a “Blue Ridge Wellness”), a dispensary in Maryland.

Subsequent Transactions

•

On July 4, 2023, the Company commenced trading of its common shares on the TSX under the new ticker symbol “TSND”. Subsequently, the ticker symbol on the OTC market was also changed to “TSNDF” effective July 6, 2023.

•

On July 10, 2023, the Company completed the acquisition of Herbiculture Inc. (“Herbiculture”) a dispensary in Maryland.

•

On July 28, 2023, subsequent to closing of the Stearns Loan, the Company met the criteria for $2,500 of restricted cash to be released.

Components of Results of Operations

The following discussion sets forth certain components of our Unaudited Condensed Consolidated Statements of Comprehensive Loss as well as ~~the acquisition of Gage (the "Gage Acquisition") in Michigan in March 2022. Retail dispensaries increased from thirteen at June 30, 2021 to twenty-six at June 30, 2022.~~factors that impact those items.

~~The increase is partially offset by the decrease of $19,505 in wholesale~~

Revenue

TerrAscend generates revenue from ~~$36,330 at June 30, 2021 to $16,825 for~~ the ~~three months ended June 30, 2022 which was mainly related~~sale of cannabis products, brands, and services to the ~~operational reconfiguration~~United States and Canadian markets. Revenues consist of wholesale and retail sales in the ~~Company's cultivation facility~~medical and legal adult use market across Canada and in ~~Pennsylvania.~~several U.S. states where cannabis has been legalized for medical or adult use.

Cost of ~~Sales~~sales

For the Three Months Ended

June 30, 2022

June 30, 2021

Cost of sales

$
34,389

$
23,773

Impairment and write downs of inventory

7,422

115

Total cost of sales

$
41,811

$
23,888

$ change

$
17,923

% change

75
%

Cost of sales as a % of revenue

65
%

41
%

~~The increase in cost~~Cost of sales ~~for~~primarily consists of expenses related to providing cannabis products and services to TerrAscend's customers, including personnel-related expenses, the ~~three months ended June 30, 2022 as compared~~depreciation of property and equipment, amortization of acquired intangible assets, and other overhead costs.

General and administrative

General and administrative ("G&A") consists primarily of personnel costs related to ~~the three months ended June 30, 2021 was driven mainly by the Gage Acquisition,~~finance, human resources, legal, and other administrative functions. Additionally G&A expense includes professional fees to third parties, as well as anmarketing expenses. In addition, G&A expense includes share-based compensation on options, restricted stock units and warrants. TerrAscend expects that G&A expense will increase in New Jersey due to the increase in adult use sales which commenced during the three months ended June 30, 2022. The increase in cost of sales as a percentage of revenue was due to lower volumes in Pennsylvania leading to under-absorption, primarily related to lower wholesale flower sales, as well as operational challenges at the Company's cultivation facility in Frederick, Marylandabsolute dollars as the ~~Company transitions to its Hagerstown location.~~business grows.

~~In addition, management wrote down its inventory by $7,422~~Amortization and ~~$115~~depreciation

Amortization and depreciation includes the amortization of intangible assets. Amortization is calculated on a straight line basis over the following terms:


Brand intangibles- indefinite lives	Indefinite useful lives
Brand intangibles- definite lives	3 years
Software	5 years
Licenses	5-30 years
Customer relationships	5 years
Non-compete agreements	3 years

Depreciation of property and equipment is calculated on a straight-line basis over the estimated useful life of the asset using the following terms:


Buildings and improvements	Lesser of useful life or 30 years
Land	Not depreciated
Machinery & equipment	5-15 years
Office furniture & production equipment	3-5 years
Right of use assets	Lease term
Assets in process	Not depreciated

Impairment of intangible assets and goodwill

Goodwill and indefinite lived intangible assets are reviewed for ~~the three months ended June 30, 2022~~impairment annually and ~~2021, respectively. The inventory write-downs~~whenever there are events or changes in the current year period were mainly due to the write down of inventory to lower of cost or market which was related to the aforementioned operational reconfiguration of its cultivation facility in Pennsylvania, write downs of inventory related to a recall by the Pennsylvania Department of Health of certain vape products produced by the Company, as well as inventory in Canadacircumstances that indicate that the ~~Company deemed unsaleable. On February 4, 2022,~~carrying amount has been impaired. TerrAscend first performs a qualitative assessment. If based on the results of a qualitative assessment it has been determined that it is more likely than ~~500 vape products were recalled by~~not that the ~~Pennsylvania's Department~~fair value of ~~Health, including several~~a reporting unit exceeds

its carrying value, additional quantitative impairment test is performed which compares the carrying value of the ~~Company's SKUs.~~ reporting unit to its estimated fair value. If the carrying value exceeds the estimated fair value, an impairment is recorded.

Definite lived intangible assets are tested for impairment when there are indications that an asset may be impaired. When indicators of impairment exist, TerrAscend performs a quantitative impairment test which compares the carrying value of the assets for intangible assets to their estimated fair values. If the carrying value exceeds the estimated fair value, an impairment is recorded.

(Gain) loss from revaluation of contingent consideration

As a result of some of its acquisitions, TerrAscend recognizes a contingent consideration payable, which is an obligation to transfer additional assets to the ~~recall,~~seller if future events occur. The liability is revalued at the ~~Company wrote off $1,071~~end of ~~inventory during the three months ended June 30, 2022. The inventory write-downs~~each reporting period to determine its fair value. A gain or loss is recognized in the ~~prior year period were related to inventory that~~other (income) expense in the ~~Company deemed unsaleable.~~

~~General~~Consolidated Statements of Operations and ~~Administrative Expense (G&A)~~

For the Three Months Ended

June 30, 2022

June 30, 2021

General and administrative expense

$
33,981

$
20,750

$ change

$
13,231

% change

64
%

G&A excluding share-based compensation

$
29,518

$
16,102

G&A excluding share-based compensation as a % of revenue

46
%

27
%

~~The increase in G&A expenses was primarily a result of increased salaries and wages of $6,178, sales and marketing expense of $3,859, and office and general expense of $2,673, which is primarily~~Comprehensive Loss as a result of the ~~Gage Acquisition in March 2022.~~revaluation.

~~Amortization and Depreciation Expense~~

For the Three Months Ended

June 30, 2022

June 30, 2021

Amortization and depreciation

$
3,016

$
1,844

$ change

$
1,172

% change

64
%

The increase in amortization and depreciation expense for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021 is primarily due to the Gage Acquisition during March 2022. The company acquired intangible assets including cultivation and processing licenses, as well as retail licenses, which are amortized over a 15 year period. The fair value of the cultivation and processing and retail licenses at acquisition were $77,198 and $53,321, respectively.

(Gain) loss on fair value of warrants and purchase option derivative asset

For the Three Months Ended

June 30, 2022

June 30, 2021

(Gain) loss on fair value of warrants and purchase option derivative asset

$
(47,345
)

$
19,891

$ change

$
(67,236
)

% change

-338
%

The Company's warrant liability ~~has been~~consists of the warrant liability acquired through its Gage Acquisition, a detachable warrant liability issued through the private placement (Note 13), and a conversion option related to the convertible debenture offering (Note 12). These warrants were recorded as a warrant liability and are remeasured to fair value at the end of each reporting unit using the Black-Scholes model. A gain or loss is recognized in the other (income) expense in the Consolidated Statements of Operations and Comprehensive Loss as a result of the revaluation.

Finance and other expenses

Finance and other expenses consists primarily of interest expense on TerrAscend's outstanding debt obligations.

Transaction and restructuring costs

Transaction costs include costs incurred in connection with TerrAscend's acquisitions, such as expenses related to professional fees, consulting, legal and accounting. Restructuring costs are those costs associated with severance and restructuring of business units.

Impairment of property and equipment

TerrAscend evaluates the recoverability of property and equipment whenever events or changes in circumstances indicate that the carrying value of the asset, or asset group, may not be recoverable. When TerrAscend determines that the carrying value of the long-lived asset may not be recoverable based upon the existence of one or more indicators, the assets are assessed for impairment based on the estimate of future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the carrying value of an asset exceeds its estimated future undiscounted cash flows, an impairment loss is recorded for the excess of the asset’s carrying value over its fair value.

Unrealized and realized foreign exchange loss

Unrealized and realized foreign exchange loss represents the loss recognized on the remeasurement of USD denominated cash and other assets recorded in the Canadian dollars functional currency at TerrAscend's Canadian operations.

Unrealized and realized gain on investments

TerrAscend accounts for its investment in equity securities without readily determinable fair values using a valuation technique which maximizes the use of relevant observable inputs, with subsequent holding changes in fair value recognized in unrealized gain or loss on investments in the consolidated statement of loss.

Provision for income taxes

Provision for income taxes consists of U.S. federal and state income taxes in certain jurisdictions in which TerrAscend conducts business.

Results from Operations- Three Months Ended June 30, 2023 and June 30, 2022

The following tables represent the Company’s results from operations for the six months ended June 30, 2023 and 2022.

Revenue, net


	For the Three Months Ended
		June 30, 2023			June 30, 2022
Revenue		$	72,437		$	64,221
Excise and cultivation taxes			(313	)		(261	)
Revenue, net		$	72,124		$	63,960
$ change		$	8,164
% change			13	%

Revenue increased from $63,960 to $72,124 driven by growth in retail offset by a decline in wholesale. Retail revenue increased from $47,979 during the three months ended June 30, 2022 to $58,254 during the three months ended June 30, 2023. The increase is primarily a result of adult use coming online in New Jersey in April 2022 and the acquisition of AMMD in Maryland in January 2023. The increase in retail revenue is partially offset by a $2,111 decrease in wholesale revenue related to declines in wholesale in the Pennsylvania market offset by growth in the wholesale market in New Jersey related to adult use sales in the state.

Cost of Sales


	For the Three Months Ended
		June 30, 2023			June 30, 2022
Cost of sales		$	34,817		$	32,587
Impairment and write downs of inventory			1,081			7,422
Total cost of sales		$	35,898		$	40,009
$ change		$	(4,111	)
% change			-10	%
Cost of sales as a % of revenue			50	%		63	%

The reduction of $4,111 in cost of sales for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022 is mainly a result of impairments and write-downs of inventory in Pennsylvania of $7,422 in the prior period.

General and Administrative Expense


	For the Three Months Ended
		June 30, 2023			June 30, 2022
General and administrative expense		$	30,476		$	32,925
$ change		$	(2,449	)
% change			-7	%

The decline in G&A expense of $2,449 for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022 was primarily a result of actions the Company undertook in the latter part of 2022 to reduce expenses and reduce its workforce in order to strengthen the position for the Company to generate positive cashflow from operations.

Amortization and Depreciation Expense


	For the Three Months Ended
		June 30, 2023			June 30, 2022
Amortization and depreciation		$	2,242		$	2,581
$ change		$	(339	)
% change			-13	%

The decrease of $339 in amortization and depreciation expense for the three months ended June 30, 2023 as compared to the three months ended June 30, 2022 is primarily due to a brand intangible asset that was fully amortized during 2022.

Gain on fair value of warrants and purchase option derivative asset


	For the Three Months Ended
		June 30, 2023			June 30, 2022
Gain on fair value of warrants and purchase option derivative asset		$	(215	)	$	(47,345	)
$ change		$	47,130
% change			-100	%

The Preferred Share warrant liability was remeasured to fair value at June 30, 2022 using the ~~Black Scholes~~Black-Scholes model. The Company recognized a gain during the three months ended June 30, 2022 as a result of the reduction of the Company's share price from March 31, ~~2021~~2022 as compared to June 30, 2022, as well as from warrants exercised during the three months ended June 30, 2022. The combined impact resulted in a gain on fair value of warrants of ~~$47,845.~~$47,345.

The Preferred Share warrant liability expired during the three months ended June 30, 2023.

For the three months ended June 30, 2022, the purchase option derivative asset related to the option to purchase an additional 6.25% ownership of the Company's New Jersey partnership, was remeasured using the Monte Carlo simulation model and resulted in a loss of $500.

During the three months ended June 30, 2021, the Company recognized a loss on fair value of warrants of $19,891 as a result of the increase in the Company's share price from December 31, 2020 to June 30, 2021 as well as warrants exercised during the three months ended June 30, 2021.

Finance and other expenses


	For the Three Months Ended						For the Three Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Finance and other expenses		$	13,902		$	8,919		$	8,171		$	13,663
$ change		$	4,983					$	(5,492	)
% change			56	%					-40	%

The ~~increase~~decrease of $5,492 in finance ~~expense~~and other expenses for the three months ended June 30, ~~2022~~2023 as compared to the three months ended June 30, ~~2021~~2022 is primarily due to ~~interest expense recognized on~~ the ~~loans acquired~~indemnification of asset release as ~~part~~a result of the ~~Gage Acquisition, as well as a loss recognized on disposal~~expiration of ~~fixed assets of $981~~escrow agreement related to ~~lights at~~ the ~~Pennsylvania cultivation facility which were discarded~~acquisition of Apothecarium during the three months ended June 30, 2022.

Transaction and restructuring costs


	For the Three Months Ended						For the Three Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Transaction and restructuring costs		$	627		$	432		$	389		$	627
$ change		$	195					$	(238	)
% change			45	%					-38	%

The ~~increase~~decrease of $238 in transaction and ~~restructuring~~restricting costs for the three months ended June 30, ~~2022~~2023 as compared to the three months ended June 30, ~~2021 was~~2022 relates primarily ~~due~~ to work done for Sarbanes Oxley implementation during the three months ended June 30, 2022.

~~Impairment of goodwill~~

26Unrealized and realized foreign exchange (gain) loss


	For the Three Months Ended						For the Three Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Impairment of goodwill		$	-		$	5,007
Unrealized and realized foreign exchange (gain) loss								$	(101	)	$	(315	)
$ change		$	(5,007	)				$	214
% change			-100	%					-68	%

The ~~impairment~~increase of ~~goodwill~~$214 in unrealized foreign exchange gain for the three months ended June 30, 2021 was related to the Company's Florida reporting unit as the Company determined that the estimated cash flows of its Arise business did not support the carrying value of the intangible assets and goodwill. As a result, the Company recorded impairment to reduce the balance of goodwill at its Florida reporting unit to $nil.

~~Impairment of intangible assets~~

For the Three Months Ended

June 30, 2022

June 30, 2021

Impairment of intangible assets

$
-

$
3,633

$ change

$
(3,633
)

% change

-100
%

~~The impairment recorded during the three months ended June 30, 2021 relates to the write-off of intellectual property at the Company's Arise business.~~

~~Unrealized and realized foreign exchange loss~~

For the Three Months Ended

June 30, 2022

June 30, 2021

Unrealized and realized foreign exchange loss

$
(306
)

$
3,055

$ change

$
(3,361
)

% change

-110
%

~~The decrease in unrealized foreign exchange loss for the three months ended June 30, 2022~~2023 as compared to the three months ended June 30, ~~2021~~2022 is a result of the remeasurement of ~~USD~~U.S. dollar denominated cash and other assets recorded in C$Canadian dollar functional currency at the Company’s Canadian operations.

~~Unrealized and realized gain on investments~~

For the Three Months Ended

June 30, 2022

June 30, 2021

Unrealized and realized loss (gain) on investments

$
234

$
(5,964
)
$ change

$
6,198

% change

-104
%

The loss on investment during the three months ended June 30, 2022 is related to the revaluation of the investments acquired through the Gage Acquisition. The gain on investment during the three months ended June 30, 2021 relates to the acquisition of the remaining 90% investment in Guadco LLC and KCR Holdings LLC on April 30, 2021.

Provision for income taxes


	For the Three Months Ended						For the Three Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Provision for income taxes		$	4,688		$	6,937		$	6,448		$	4,688
$ change		$	(2,249	)				$	1,760
% change			-32	%					38	%

The ~~decrease~~increase in provision for income taxes for the three months ended June 30, ~~2022~~2023 as compared to the three months ended June 30, ~~2021~~2022 was ~~due to~~primarily driven by the ~~decline in revenue and associated decline~~increase in gross profit ~~mainly related to the operational reconfiguration~~as a result of ~~the Company's cultivation facility~~growth in ~~Pennsylvania.~~new jurisdictions.

Results from Operations- Six ~~months ended~~Months Ended June 30, ~~2022~~2023 and June 30, ~~2021~~2022

The following tables represent the Company’s results from operations for the six months ended June 30, ~~2022~~2023 and ~~2021.~~2022.

Revenue, net

2732


	For the Six Months Ended							For the Six Months Ended
		June 30, 2022			June 30, 2021				June 30, 2023			June 30, 2022
Revenue		$	115,812		$	118,473			$	142,157		$	113,281
Excise and cultivation taxes			(1,349	)		(6,396	)			(635	)		(736	)
Revenue, net		$	114,463		$	112,077			$	141,522		$	112,545
$ change		$	2,386						$	28,977
% change			2	%						26	%

~~The increase in net revenue at June 30, 2022 as compared~~

Revenue increased from $112,281 to June 30, 2021 was due to an increase in retail revenue of $36,334 from $37,363 for the six months ended June 30, 2021 to $73,697 for the six months ended June 30, 2022. The increase in revenue is mainly due to adult use sales in New Jersey which commenced$141,522 during the six months ended June 30, ~~2022,~~2023 as ~~well as the Gage Acquisition. Retail dispensaries increased from thirteen at June 30, 2021~~compared to ~~twenty-six at June 30, 2022.~~

~~This increase is partially offset by a decrease of $33,948 in wholesale revenue from $74,714 for the six months ended June 30, 2021 to $40,766 for~~ the six months ended June 30, 2022 ~~which was mainly related to~~driven by growth in retail offset by a decline in wholesale. The growth in retail was driven by the ~~Canada business, as well as~~conversion to adult use in New Jersey, the ~~operational reconfiguration~~acquisition of Gage in March 2022, and the ~~Company's cultivation facility~~acquisition of AMMD in January 2023. The decline in wholesale was driven by market dynamics in Pennsylvania ~~as well as~~and the ~~aforementioned vape recall. As a result of the recall,~~decision the Company ~~recorded sales returns of $1,040 during the six months ended June 30, 2022.~~made to discontinue bulk wholesale in Michigan, partially offset by an increase in New Jersey driven by adult use implementation.

Cost of Sales


	For the Six Months Ended							For the Six Months Ended
		June 30, 2022			June 30, 2021				June 30, 2023			June 30, 2022
Cost of sales		$	67,835		$	41,601			$	70,315		$	65,663
Impairment and write downs of inventory			8,495			699				1,081			7,307
Total cost of sales		$	76,330		$	42,300			$	71,396		$	72,970
$ change		$	34,030						$	(1,574	)
% change			80	%						-2	%
Cost of sales as a % of revenue			67	%		38	%			50	%		65	%

The ~~increase~~reduction of $1,574 in cost of sales for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021 was driven~~2022 is mainly bya result of impairments and write downs of inventory in Pennsylvania of $7,422 in the ~~Gage Acquisition, as well as an increase in New Jersey due to adult use sales which commenced during the six months ended June 30, 2022.~~ prior year.

General and Administrative Expense


	For the Six Months Ended
		June 30, 2023			June 30, 2022
General and administrative expense		$	58,206		$	54,349
$ change		$	3,857
% change			7	%

The increase in ~~cost~~G&A expense of sales as a percentage of revenue was primarily due to lower wholesale flower sales volume in Pennsylvania leading to under-absorption, and unfavorable mix, primarily related to lower Gage bulk wholesale sales at the end of the first quarter.

~~In addition, management wrote down its inventory by $8,495 and $699~~$3,857 for the six months ended June 30, ~~2022 and 2021, respectively. The inventory write-downs in the current year period were mainly due~~2023 as compared to the write down of inventory to lower of cost or market which was related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania, write downs of inventory related to the vape recall, as well as inventory in Canada that the Company deemed unsaleable. As a result of the recall, the Company wrote off $1,925 of inventory during the six months ended June 30, ~~2022. The inventory write-downs in the prior year period were related to inventory that the Company deemed unsaleable.~~

~~General and Administrative Expense (G&A)~~

For the Six Months Ended

June 30, 2022

June 30, 2021

General and administrative expense

$
56,533

$
41,142

$ change

$
15,391

% change

37
%

G&A excluding share-based compensation

$
48,714

$
32,927

G&A excluding share-based compensation as a % of revenue

43
%

29
%

~~The increase in G&A expenses~~2022 was primarily a result of ~~increased salaries~~expenses related to implementation of adult use in New Jersey in April 2022 and ~~wages~~the acquisition of ~~$7,815, sales and marketing~~Gage in March 2022, partially offset by expense reductions the Company undertook during the second half of ~~$4,464, and office and general expense of $2,384, which is primarily a result~~2022 across all areas of the ~~Gage Acquisition.~~Company as part of its plan to streamline operations and drive positive cashflow.

Amortization and Depreciation Expense

For the Six Months Ended

June 30, 2022

June 30, 2021

Amortization and depreciation

$
5,634

$
3,717

$ change

$
1,917

% change

52
%


	For the Six Months Ended
		June 30, 2023			June 30, 2022
Amortization and depreciation		$	4,271		$	4,756
$ change		$	(485	)
% change			-10	%

The ~~increase~~decrease of $485 in amortization and depreciation expense for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021~~2022 is primarily due to ~~the Gage Acquisition. The Company acquired~~a brand intangible ~~assets including cultivation and processing licenses, as well as retail licenses, which are~~asset that was fully amortized ~~over a 15 year period. The fair value of the cultivation and processing licenses and retail licenses at acquisition were $77,198 and $53,321, respectively.~~during 2022.

~~Revaluation of contingent consideration~~

For the Six Months Ended

June 30, 2022

June 30, 2021

Revaluation of contingent consideration

$
153

$
2,990

$ change

$
(2,837
)

% change

-95
%

The decrease in the revaluation of contingent consideration for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 is a result of a reduction in the liability as compared to June 30, 2021 due to payments for the earnout of Ilera of $29,668, and State Flower of $7,040 made subsequent to June 30, 2021, reducing the amount outstanding. This decrease is partially offset by the accretion of the contingent consideration payable for KCR, which are recorded at the present value of future payments upon initial recognition.

~~(Gain) loss~~Gain on fair value of warrants and purchase option derivative asset


	For the Six Months Ended						For the Six Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
(Gain) loss on fair value of warrants and purchase option derivative asset		$	(53,058	)	$	25,301
Gain on fair value of warrants and purchase option derivative asset								$	(653	)	$	(53,058	)
$ change		$	(78,359	)				$	52,405
% change			-310	%					-99	%

The Preferred Share warrant ~~liabilities have been~~liability was remeasured to fair value at June 30, 2022 using the ~~Black Scholes~~Black-Scholes model. The Company recognized a ~~gain~~loss during the six months ended June 30, 2022 as a result of the reduction of the Company's share price from ~~December 31, 2021~~June 30, 2022 as compared to June 30, ~~2022, as well as from warrants exercised~~2022.

The Preferred Share warrant liability expired during the six months ended June 30, ~~2022. The combined impact resulted in a gain on fair value of warrants of $53,876.~~2023.

For the six months ended June 30, 2022, the purchase option derivative asset related to the option to purchase an additional 6.25% ownership of the Company's New Jersey partnership, was remeasured using the Monte Carlo simulation model and resulted in a loss of $818.

During the six months ended June 30, 2021 the Company recognized a loss on fair value of warrants of $25,301 as a result of the increase in the Company's share price from December 31, 2020 to June 30, 2021 as well as warrants exercised during the six months ended June 30, 2021.

Finance and other expenses


	For the Six Months Ended						For the Six Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Finance and other expenses		$	20,758		$	15,309		$	18,258		$	20,318
$ change		$	5,449					$	(2,060	)
% change			36	%					-10	%

The ~~increase~~decrease of $2,060 in finance ~~expense~~and other expenses for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021~~2022 is primarily due to interest expense recognized on the loans ~~acquired~~ as part of the Gage ~~Acquisition.~~acquisition which closed on March 10, 2022.

Transaction and restructuring costs


	For the Six Months Ended						For the Six Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Transaction and restructuring costs		$	1,242		$	432		$	392		$	1,242
$ change		$	810					$	(850	)
% change			188	%					-68	%

The ~~increase~~decrease of $850 in transaction and ~~restructuring~~restricting costs for the ~~six~~three months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021 was~~2022 relates primarily ~~due~~ to the Gage Acquisition, ~~as well as work done for Sarbanes Oxley implementation.~~

~~Impairment of goodwill~~

For the Six Months Ended

June 30, 2022

June 30, 2021

Impairment of goodwill

$
-

$
5,007

$ change

$
(5,007
)

% change

-100
%

The impairment of goodwill for the six months ended June 30, 2021 was related to the Company's Florida reporting unit as the Company determined that the estimated cash flows of its Arise business did not support the carrying value of the intangible assets and goodwill. As a result, the Company recorded impairment to reduce the balance of goodwill at its Florida reporting unit to $nil.

~~Impairment of intangible assets~~

For the Six Months Ended

June 30, 2022

June 30, 2021

Impairment of intangible assets

$
-

$
3,633

$ change

$
(3,633
)

% change

-100
%

~~The impairment recorded during the six months ended June 30, 2021 relates to the write-off of intellectual property at the Company's Arise business.~~which closed on March 10, 2022.

Unrealized and realized foreign exchange loss


	For the Six Months Ended						For the Six Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Unrealized and realized foreign exchange loss		$	50		$	5,838
Unrealized and realized foreign exchange loss (gain)								$	(132	)	$	41
$ change		$	(5,788	)				$	(173	)
% change			-99	%					-422	%

The decrease of $173 in unrealized foreign exchange loss for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021~~2022 is a result of the remeasurement of ~~USD~~U.S. dollar denominated cash and other assets recorded in C$Canadian dollar functional currency at the Company’s Canadian operations.

~~Unrealized and realized gain on investments~~

For the Six Months Ended

June 30, 2022

June 30, 2021

Unrealized and realized loss (gain) on investments

$
234

$
(6,192
)
$ change

$
6,426

% change

-104
%

The loss on investment during the six months ended June 30, 2022 is related to the revaluation of the investments acquired through the Gage Acquisition. The gain on investment during the six months ended June 30, 2021 relates to the acquisition of the remaining 90% investment in Guadco LLC and KCR Holdings LLC on April 30, 2021.

Provision for income taxes


	For the Six Months Ended						For the Six Months Ended
		June 30, 2022			June 30, 2021			June 30, 2023			June 30, 2022
Provision for income taxes		$	8,431		$	16,373		$	19,112		$	8,431
$ change		$	(7,942	)				$	10,681
% change			-49	%					127	%

The ~~decrease~~increase in provision for the income taxes for the six months ended June 30, ~~2022~~2023 as compared to the six months ended June 30, ~~2021~~2022 was ~~due to~~primarily driven by the ~~decline in revenue and associated decline~~increase in gross profit ~~mainly related to the operational reconfiguration~~as a result of ~~the Company's cultivation facility~~growth in ~~Pennsylvania, as well as the vape recall by the Pennsylvania Department of Health.~~new jurisdictions.

Liquidity and Capital Resources


	June 30, 2023			December 31, 2022
	$			$
Cash and cash equivalents		28,915			26,158
Restricted Cash		3,106			605
Current assets		106,629			121,993
Non-current assets		615,119			579,594
Current liabilities		133,489			137,905
Non-current liabilities		292,660			242,511
Working capital		(26,860	)		(15,912	)
Total shareholders' equity		295,599			321,171

3034

June 30, 2022

December 31, 2021

$

$

Cash and cash equivalents

48,426

79,642

Current assets

137,318

143,221

Non-current assets

871,299

438,713

Current liabilities

140,403

61,044

Non-current liabilities

323,246

291,936

Working capital

(3,085
)

82,177

Total shareholders' equity

544,968

228,954

The calculation of working capital provides additional information and is not defined under GAAP. ~~The Company~~TerrAscend defines working capital as current assets less current liabilities. This measure should not be considered in isolation or as a substitute for any standardized measure under GAAP.

Liquidity and going concern

At June 30, ~~2022,~~2023, TerrAscend had ~~cash~~an accumulated deficit of $653,623. During the three and six months ended June 30, 2023, TerrAscend incurred a net loss from continuing operations of $12,855 and $32,033, respectively. Additionally, as of June 30, 2023 the Company’s current liabilities exceed its current assets. Therefore, it is possible that the Company may need additional capital to continue to fund its operations.

The aforementioned indicators raise substantial doubt about TerrAscend's ability to continue as a going concern for at least one year from the issuance of these financial statements. The Company believes this concern is mitigated by steps to improve its operations and cash ~~equivalents~~position, including: (i) identifying access to future capital required to meet the Company’s on-going obligations, (ii) improved cashflow growth from TerrAscend's consolidated operations, particularly in New Jersey and most recently Maryland with conversion to adult use sales, and (iii) various cost and efficiency improvements.

Since its inception, TerrAscend's primary sources of ~~$48,426, which is sufficient~~capital have been through the issuance of equity securities or debt facilities, and TerrAscend has received aggregate net proceeds from such transactions totaling $654,000 as of June 30, 2023.

TerrAscend expects to fund ~~the Company’s ongoing operations. Any~~any additional future requirements ~~will be funded~~ through the following sources of capital:

•

~~Cash~~cash from ongoing operations.

•

~~Market~~market offerings.

•

~~Debt - the Company may seek to obtain~~ additional debt from additional creditors.

•

~~Sale leaseback - the Company may seek to sell and lease back its capital properties.~~sale of real property.

•

~~Exercise of options and warrants - the Company would receive funds from~~ sale leaseback transactions.

•

exercise of options and ~~warrants from~~warrants.

Capital requirements

The Company has $208,659 in principal amounts of loans payable at June 30, 2023. Of this amount, $22,336 are due within the ~~holders of such securities~~next twelve months.

TerrAscend has entered into leases for certain premises and offices for which it owes monthly lease payments. TerrAscend has $78,204 in lease obligations. Of this amount, $6,151 are due in the ~~event they~~next twelve months. Additionally, TerrAscend makes monthly payments on financing obligations on six of its real estate properties with $14,691 payable, $1,944 of which is due in the next twelve months.

TerrAscend's undiscounted contingent consideration payable is $4,434 at June 30, 2023. The contingent consideration payable relates to TerrAscend's business acquisitions of the Apothecarium and State Flower and is due in the next twelve months.

During the year ended December 31, 2020, TerrAscend expensed $7,500 related to amounts payable to an entity controlled by the minority shareholders of TerrAscend NJ pursuant to services surrounding the granting of certain licenses. The final payment of $3,750 was made in July 2023.

At June 30, 2023, the Company had accounts payable and accrued liabilities of $50,841 and corporate income taxes payable of $45,934.

TerrAscend does not have any off-balance sheet arrangements that have, or are ~~exercised.~~reasonably likely to have, a current or future effect on TerrAscend's results of operations or financial condition, including and without limitation, such consideration as liquidity and capital resources.

~~The Company’s~~

TerrAscend intends to meet its capital commitments through any or all of the sources of capital noted above. TerrAscend's objective with respect to its capital management is to ensure it has sufficient cash resources to maintain its ongoing operations and finance its research and development activities, corporate and administration expenses, working capital and overall capital expenditures. Since inception, the Company has primarily financed its liquidity needs through the issuance of shares and utilization of borrowings.future obligations.

~~The Company has $280,136 in principal amounts~~

Debt facilities

Ilera Term Loan

On December 18, 2020, WDB Holding PA, a subsidiary of ~~loans payable at June 30, 2022. Of this amount, $68,955 are due within the next twelve months. The Company has~~TerrAscend, entered into ~~operating leases for~~a senior secured term loan with a syndicate of lenders in the amount of $120,000 ("Ilera Term Loan"). The term loan bears interest at 12.875% per annum and matures on December 17, 2024. TerrAscend has the ability to increase the facility by up to $30,000. WDB Holding PA's obligation under the Ilera Term Loan and related transaction documents are guaranteed by TerrAscend, TerrAscend USA, Inc., and certain ~~premises~~subsidiaries of WDB Holding PA, and ~~offices for which it owes monthly lease~~secured by TerrAscend USA Inc.'s equity interest in WDB Holding PA and substantially all of the assets of WDB Holding PA and the subsidiary guarantors party thereto. The loan can be refinanced at the option of the borrower after 18 months from the closing date subject to a premium payment due. Of the total proceeds received, $105,767 was used to satisfy the remaining Ilera earn-out payments.

~~In addition,~~

On April 28, 2022, the ~~Company's undiscounted contingent consideration payable is $10,734 at June 30, 2022. The contingent consideration payable relates~~Ilera Term Loan was amended to provide WDB Holding PA with greater flexibility by resetting the Company's business acquisitions of The Apothecarium, State Flower, and KCR. Contingent consideration is based upon the potential earnout of the underlying business unit and is measured at fair value using a projection model for the business and the formulaic structure for determining the consideration under the agreement. The contingent consideration is revaluedminimum consolidated interest coverage ratio levels that must be satisfied at the end of each ~~reporting period.~~measurement period and extending the date in which WDB Holding PA is required to deliver its budget for the fiscal year ending December 31, 2021. In addition, the no-call period was extended from 18 months to 30 months, subject to a premium payment. This modification was not considered extinguishment of debt under ASC 470 Debt.

On November 11, 2022, WDB Holding PA, TerrAscend, TerrAscend USA Inc. and the subsidiary guarantors party to the Ilera Term Loan and the PA Agent (on behalf of the required lenders) entered into an amendment to the PA Credit Agreement, pursuant to which PA Agent and the required lenders agreed that WDB Holding PA's obligation to maintain the consolidated interest coverage ratio as set forth in the PA Credit Agreement for the period ended September 30, 2022, shall not apply, subject to certain conditions, including (but not limited to) an obligation to enter into a subsequent amendment agreement on or before December 15, 2022, documenting certain enhancements and amendments to the PA Credit Agreement to be agreed. In addition, WDB Holding PA offered a prepayment of $5,000 pro rata to all lenders holding outstanding loans thereunder at a price equal to 103.22% of the principal amount prepaid, plus accrued and unpaid interest.

On December 21, 2022, WDB Holding PA completed an amendment to reduce TerrAscend's principal debt by $35,000 and annual interest expense by $5,000. TerrAscend agreed to make a $35,000 payment at the original prepayment price of 103.22% to par, and agreed to use commercially reasonable efforts to add certain collateral to Ilera Term Loan, collectively by March 15, 2023. The amendment further provided that should WDB Holding PA not maintain the prescribed interest coverage ratio, the Company shall be required to deposit funds, as outlined in the amendment, into a restricted account, and no event of default shall occur. This amendment was not considered extinguishment of debt under ASC 470 Debt.

On March 15, 2023, WDB Holding PA, in exchange for a fee in the amount of 1% of the then outstanding principal loan balance, agreed to an amendment among other things, to (i) extend the obligation date to prepay TerrAscend's debt from March 15, 2023 to June 30, 2023 in which WDB Holding PA must use commercially reasonable efforts to add additional collateral to the Ilera Term Loan, (ii) increase the amount of debt to be reduced by up to $37,000, subject to certain reductions in amount based on meeting certain time based milestones, at a prepayment price of 103.22% to par, and (iii) extend the next test date in respect of the interest coverage ratio until June 30, 2023. This amendment was not considered extinguishment of debt under ASC 470 Debt. There is $115,000 of principal amounts outstanding at March 31, 2023.

On April 14, 2023, WDB Holding PA agreed to an amendment to the Ilera Term Loan to, among other things, to (i) permit changes necessary for the TSX Transaction (as defined therein), and (ii) to waive certain tax provisions.

On June 22, 2023, WDB Holding PA further agreed to an amendment among other things, to (i) extend the next test date for the interest coverage ratio from June 30, 2023to September 30, 2023, and (ii) amend the terms for which WDB Holding PA may incur certain indebtedness and liens.

Gage Loans

The Gage Acquisition included a senior secured term loan (the "Original Gage Term Loan") with an acquisition date fair value of $53,857. The credit agreement bears interest at a rate equal to the greater of (i) the Prime Rate plus 7% or (ii) 10.25%. The term loan is payable monthly and matures on November 30, 2022. The term loan is secured by a first lien on all Gage assets.

On August 10, 2022, the Original Gage Term Loan was amended as a result of the corporate restructure in conjunction with the Gage Acquisition. The amendment to the Original Gage Term Loan includes the addition of a borrower and guarantor under the term loan and a right of first offer in favor of the administrative agent for a refinancing of the term loan. This amendment was not considered extinguishment of debt under ASC 470 Debt.

On November 29, 2022, TerrAscend repaid $30,000 outstanding principal amount on the Original Gage Term Loan. On November 30, 2022, the remaining loan principal amount of $25,000 on the Original Gage Term Loan was amended (the "Amended Gage Term Loan"). The Amended Gage Term Loan bears interest on $25,000 at a per annum rate equal to the greater of (i) the U.S. "prime rate" plus 6.00%, and (ii) 13.0% and matures on November 1, 2024. Commencing on May 31, 2023, TerrAscend will make monthly principal repayments of 0.40% of the aggregate principal amount outstanding. Additionally, the unpaid principal amount of the loan shall bear paid in kind interest at a rate of 1.50% per annum. No prepayment fees are owed if TerrAscend voluntarily prepays the loan after 18 months. If such prepayment occurs prior to 18 months, a prepayment fee equal to all of the interest on the loans that would be due after the date of such prepayment, is owed. Under the Amended Gage Term Loan, TerrAscend has the ability to borrow incremental term loans of $30,000 at the option of TerrAscend and subject to consents from the required lenders. The additional $30,000 incremental term loans available under the amendment have not been drawn as of December 31, 2022. This loan represents a loan syndication, and therefore TerrAscend assessed each of the lenders separately under ASC 470 Debt to determine if this represents a modification, or an extinguishment of debt. For three of the four remaining lenders, it was determined that this was a modification. For the remaining lender, it was determined that this represented an extinguishment of debt and therefore the fees paid to the lenders on modification were expensed. As a result of this transaction, TerrAscend expensed $1,907 of fees paid to the lenders and third parties as they did not meet the criteria for capitalization under ASC 470 Debt.

Additionally, the Gage Acquisition included a loan payable to a former owner of a licensed entity with an acquisition date fair value of $2,683, and a promissory note with an acquisition date fair value of $4,065. The loan payable to the former owner bears interest at a rate of 0.2%. The promissory note bears interest at a rate of 6%. There is $4,583 of principal amounts outstanding at June 30, 2023 on the loan payable and promissory note.

On June 9, 2023, TerrAscend Growth Corp. agreed to an amendment among other things, to (i) permit changes necessary for the TSX Transaction (as defined therein) and (ii) to permit certain indebtedness and waive certain tax provisions.

This amendment was not considered extinguishment of debt under ASC 470 Debt.

Pinnacle Loans

The Pinnacle Acquisition purchase price included two promissory notes in an aggregate amount of $10,000 to pay down all Pinnacle liabilities and encumbrances. The promissory note matures on June 30, 2023 and bears interest rates of 6%. On June 27, 2023, Spartan Partners Properties, LLC, agreed to an amendment among other things, to extend the obligation date of the loan until December 1, 2023. There is $8,833 of principal amounts outstanding at March 31, 2023 on the two promissory notes.

Pelorus Term Loan

On October 11, 2022, subsidiaries of TerrAscend, among others, entered into a loan agreement with Pelorus Fund REIT, LLC ("Pelorus") for a single-draw senior secured term loan ("Pelorus Term Loan") in an aggregate principal amount of $45,478. The Pelorus Term Loan bears interest at a variable rate tied to the one month secured overnight financing rate (SOFR), subject to a base rate, plus 9.5%, with interest-only payments for the first 36 months. The base rate is defined as, on any day, the greatest of (i) 2.5%, (b) the effective federal funds rate in effect on such day plus 0.5%, and (c) one month SOFR in effect on such day. The obligations of the borrowers under the Pelorus Term Loan are guaranteed by TerrAscend, TerrAscend USA Inc. and certain other subsidiaries of TerrAscend and secured by all of the assets of TerrAscend's Maryland and New Jersey businesses, including certain real estate in Maryland and New Jersey, but excludes all MD dispensaries. The Pelorus Term Loan matures on October 11, 2027. There is $45,478 of principal amounts outstanding at June 30, 2023.

This amendment was not considered extinguishment of debt under ASC 470 Debt.

Stearns Loan

On June 26, 2023, the Company closed on a $25,000 commercial loan with Stearns Bank, secured by the Company's cultivation facility in Pennsylvania and its AMMD dispensary in Cumberland, Maryland. The Company ~~expects~~is required to hold $2,500 on deposit in a restricted account. The loan carries an interest rate of prime plus 2.25% and matures in December 2024. The proceeds from the loan were used to pay down the Company's higher interest rate debt, thereby lowering the Company's overall interest expense.

Class A Share of TerrAscend Growth

As a part of the Reorganization (Note 3), TerrAscend Growth Corp. issued $ 1 million of Class A shares with a 20% guaranteed annual dividend. Under the Subscription Agreement, TerrAscend Growth Corp holds a call right to repurchase all of the Class A Shares, at any point in time, issuable to the holder of Class A shares and the holder of Class A shares is granted a put right that ~~its cash~~is exercisable at any time following the five-year anniversary of the closing of the investment. The instrument is considered as a debt due to the economic characteristics and risks.

IHC Real Estate LP Loan

On June 26, 2023, the Company bought out the minority interest in IHC Real Estate LP and entered into a promissory note of $7,500. The promissory note carries an interest rate of 15% and matures on ~~hand and cash flows from operations, along with financing transactions, will be adequate to meet its capital requirements and operational needs for at least~~January 15, 2024. On June 28, 2023, the ~~next 12 months.~~Company made a payment of $1,500.

Cash Flows

Cash ~~Flows~~

~~Cash~~ flows ~~from~~(used in) / provided by operating activities

For the Six Months Ended

June 30, 2022

June 30, 2021

Net cash used in operating activities

$
(34,976
)

$
(10,076
)


	For the Six Months Ended
		June 30, 2023		June 30, 2022
Net cash (used in) / provided by operating activities		$	9,120	$	(34,976	)

The increase of $44,096 in net cash ~~used in~~provided by operating activities for the six months ended June 30, 2023 as compared to June 30, 2022 is due primarily ~~due~~ to lower interest of $5,832, reduced taxes of $22,127, and an increase in ~~loss from operations~~accounts payable and accrued liabilities and other payables of $11,929 due to ~~$24,034 from a profit~~timing of ~~$24,918~~those payments, offset by an increase in ~~the prior year period, as well as changes in working capital items~~inventory of ~~$16,081.~~$8,059.

Cash flows ~~from~~used in investing activities


	For the Six Months Ended
		June 30, 2023			June 30, 2022
Net cash (used in) investing activities		$	(4,877	)	$	(39	)

31The net cash used in investing activities for the six months ended June 30, 2023 primarily relates to the cash paid for the acquisition of three dispensaries in Maryland. Additionally, TerrAscend increased the investment in property and equipment by $5,426 during the six months ended June 30, 2023.

For the Six Months Ended

June 30, 2022

June 30, 2021

Net cash provided used in investing activities

$
(39
)

$
(63,387
)

~~The~~In comparison, the net cash used in investing activities for the six months ended June 30, 2022 primarily relates to investments in property and equipment of $12,500 and deposits for property and equipment of $10,036, primarily related to the buildout of a cultivation site in Maryland, continuing renovations at the Company's Pennsylvania cultivation site, as well as the continued buildout of the Company's Lodi alternative treatment center in New Jersey. Additionally, the Company had investments in intangible assets of $1,330, primarily related to adult use licenses in New Jersey. The cash used in investing activities is offset by cash inflows of $24,716 related to the cash acquired through the Gage Acquisition.

~~In comparison, the net~~Cash flows provided by financing activities


	For the Six Months Ended
		June 30, 2023		June 30, 2022
Net cash provided by financing activities		$	4,416	$	8,781

Net cash ~~used in investing~~provided by financing activities for the six months ended June 30, ~~2021~~2023 was primarily ~~relates~~due to cash ~~consideration~~inflow as a result of transfer with recourse of Employee Retention Credit of $12,677, net proceeds from the commercial loan with Stearns bank of $23,872, and net proceeds from private placements of $19,218, offset by loan principal paid ~~for the acquisitions~~ of ~~KCR~~$40,359 and ~~HMS totaling $42,736. Additionally, the Company had investments in property and equipment~~distributions to minority partners of $10,856 primarily related to the buildout of the New Jersey operations and expansions in Pennsylvania cultivation and $10,583 related to deposits paid for expansion of the cultivation premises in Pennsylvania.$3,415.

~~Cash flows from financing activities~~

For the Six Months Ended

June 30, 2022

June 30, 2021

Net cash provided by financing activities

$
8,781

$
168,507

During the six months ended June 30, 2022, 7,989,436 Common Share warrants were exercised for total proceeds of $23,797 and 88,015 stock options were exercised for total gross proceeds of $361. The cash provided by financing activities was offset by payments of contingent consideration related to the acquisition of State Flower of $6,630, loan principal payments of $5,203, loan amendment fee paid on the modification of the Ilera term loan of $1,200, and tax distributions paid on behalf of the partners of the New Jersey operations of $1,436.

Net cash provided by financing activities for the six months ended June 30, 2021, was mainly the result of the private placement on January 28, 2021, in which the Company issued 18,115,656 Common Shares at a price of $9.64 (C$12.35) per Common Share for total proceeds of $173,477, net of share issuance costs of $1,643. Additionally, during the six months ended June 30, 2021, 2,590,178 Common Share warrants were exercised for total proceeds of $6,777 and 699,009 stock options were exercised at $0.67-$6.93 (C$0.85-$8.52) per unit for total gross proceeds of $2,385. In addition, 1,900 preferred share warrants were exercised at $3,000 per unit for total gross proceeds of $3,759. The cash provided by financing activities was offset by payments of contingent consideration related to the acquisition of Ilera of $18,274.38

Reconciliation of Non-GAAP Measures

In addition to reporting the financial results in accordance with GAAP, ~~the Company~~TerrAscend reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. ~~The Company~~TerrAscend believes that certain investors and analysts use these ~~measures~~metrics to measure a ~~company's~~company’s ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and ~~the Company~~TerrAscend calculates (i) Adjusted gross profit as gross profit from continuing operations adjusted for certain material non-cash items, and (ii) Adjusted EBITDA from continuing operations as EBITDA from continuing operations adjusted for certain material non-cash items and certain other adjustments which management believes are not reflective of the ongoing operations and performance. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. ~~The Company~~

TerrAscend believes ~~this definition~~Adjusted EBITDA from continuing operations is a useful performance measure to assess the performance of ~~the Company~~TerrAscend as it provides more meaningful ongoing operating results by excluding the effects of expenses that are not reflective of ~~the Company's~~TerrAscend’s underlying business performance and other one-time or non-recurring expenses.

The table below reconciles net loss to EBITDA from continuing operations and Adjusted EBITDA from continuing operations for the three and six months ended June 30, ~~2022~~2023 and ~~2021.~~2022:

For the Three Months Ended

For the Six Months Ended

Notes

June 30, 2022

June 30, 2021

June 30, 2022

June 30, 2021

Net income (loss)

$
14,162

$
(29,662
)

$
(1,844
)

$
(43,773
)
Add (deduct) the impact of:

Provision for income taxes

4,688

6,937

8,431

16,373

Finance expenses

9,427

6,424

16,125

11,783

Amortization and depreciation

7,046

3,529

12,131

7,050

EBITDA
(a)

35,323

(12,772
)

34,843

(8,567
)
Add (deduct) the impact of:

Relief of fair value upon acquisition
(b)

549

567

2,355

567

Non-cash write downs of inventory
(c)

5,894

449

5,894

449

Vape recall
(d)

1,071

-

2,965

—

Share-based compensation
(e)

4,463

4,648

7,819

8,215

Impairment of goodwill and intangible assets
(f)

-

8,640

-

8,640

Loss on disposal of fixed assets
(g)

929

36

929

36

Revaluation of contingent consideration
(h)

34

(7
)

153

2,990

Restructuring costs and executive severance
(i)

-

467

-

467

Legal settlements
(j)

-

740

—

2,121

Other one-time items
(k)

924

860

2,898

1,122

(Gain) loss on fair value of warrants and purchase option derivative asset
(l)

(47,345
)

19,891

(53,058
)

25,301

Indemnification asset release
(m)

3,998

2,599

3,973

3,796

Unrealized and realized loss (gain) on investments
(n)

234

(5,964
)

234

(6,192
)
Unrealized and realized foreign exchange loss
(o)

(306
)

3,055

50

5,838

Adjusted EBITDA

$
5,768

$
23,209

$
9,055

$
44,783


		For the Three Months Ended						For the Six Months Ended

	Notes	June 30, 2023			June 30, 2022			June 30, 2023			June 30, 2022
Net loss		$	(13,476	)	$	14,162		$	(36,245	)	$	(1,844	)
Loss from discontinued operations			621			2,697			4,212			4,953
Loss from continuing operations			(12,855	)		16,859			(32,033	)		3,109

Add (deduct) the impact of:
Provision for income taxes			6,448			4,688			19,112			8,431
Finance expenses			7,963			10,315			15,838			16,920
Amortization and depreciation			4,991			6,493			9,762			11,018
EBITDA from continuing operations	(a)		6,547			38,355			12,679			39,478
Add (deduct) the impact of:
Relief of fair value upon acquisition	(b)		—			549			—			2,355
Non-cash write downs of inventory	(c)		—			5,894			—			5,894
Vape recall	(d)		—			1,071			—			2,965
Share-based compensation	(e)		1,981			4,463			3,694			7,819
Loss from revaluation of contingent consideration	(f)					34			0			153
Other one-time items	(g)		2,932			924			4,290			2,898
Employee Retention Credits Transfer Fee	(h)		—			—			2,235			—
Loss on lease termination and derecognition of ROU asset	(i)		—			—			205			—
Gain on fair value of warrants and purchase option derivative asset	(j)		(215	)		(47,345	)		(653	)		(53,058	)
Indemnification asset release	(k)		—			3,998			—			3,973
Impairment of property and equipment and loss on disposal of fixed assets	(l)		10			929			345			929
Unrealized and realized loss on investments	(m)		1,661			234			2,360			234
Unrealized and realized foreign exchange loss	(n)		(101	)		(315	)		(132	)		41
Adjusted EBITDA from continuing operations		$	12,815		$	8,791		$	25,023		$	13,681

TerrAscend calculates adjusted gross profit by adjusting gross profit for the one-time relief of fair value of inventory upon acquisition, non-cash write downs of inventory, vape recall, and other one time adjustments to gross profit as TerrAscend does not believe that these impacts are reflective of ongoing operations. The table below reconciles gross profit to adjusted gross profit for the three and six months ended June 30, ~~2022~~2023 and ~~2021.~~2022:

For the Three Months Ended

For the Six Months Ended

Notes

June 30, 2022

June 30, 2021

June 30, 2022

June 30, 2021

Gross profit

$
22,993

$
34,835

$
38,133

$
69,777

Add (deduct) the impact of:

Relief of fair value upon acquisition
(b)

549

567

2,355

567

Non-cash write downs of inventory
(c)

5,894

449

5,894

449

Vape recall
(d)

1,071

-

2,965

-

Accelerated depreciation
(p)

-

-

238

-

$
30,507

$
35,851

$
49,585

$
70,793




		For the Three Months Ended				For the Six Months Ended
	Notes	June 30, 2023		June 30, 2022		June 30, 2023		June 30, 2022
Gross profit		$	36,226	$	23,951	$	70,126	$	39,575
Add (deduct) the impact of:
Relief of fair value upon acquisition	(b)		—		549		—		2,355
Non-cash write downs of inventory	(c)		—		5,894		—		5,894
Vape recall	(d)		—		1,071		—		2,965
Other one time adjustments to gross profit	(g)		—		—		94		238
Adjusted gross profit		$	36,226	$	31,465	$	70,220	$	51,027

~~(a)~~a)

EBITDA from continuing operations is a non-GAAP measure and is calculated as earnings from continuing operations before interest, tax, depreciation and amortization.

~~(b)~~b)

In connection with ~~the Company's~~TerrAscend's acquisitions, inventory was acquired at fair value, which included a markup or markdown for profit. Recording inventory at fair value in purchase accounting has the effect of increasing or decreasing inventory and thereby increasing or decreasing cost of sales as compared to the amounts ~~the Company~~TerrAscend would have recognized if the inventory was sold through at cost. The write-up or down of acquired inventory represents the incremental cost of sales that were recorded during purchase accounting.

~~(c)~~c)

Represents inventory write downs outside of the normal course of operations. These inventory write-downs were related to the the write down of aged inventory to lower of cost or market which was related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania.

~~(d)~~d)

On February 4, 2022, more than 500 vape products were recalled by the Pennsylvania's Department of Health, including several of the ~~Company's~~TerrAscend's SKUs. As a result of the recall ~~the Company~~TerrAscend recorded sales returns of ~~$nil and~~ $1,040 and write-downs of inventory of ~~$1,071 and $1,925~~$854 for the three ~~and six~~ months ended ~~June 30, 2022, respectively.~~March 31, 2022.

~~(e)~~e)

Represents non-cash share-based compensation expense.

~~(f)~~

~~Represents impairment charges taken on the Company's intangible assets and goodwill.~~

~~(g)~~

~~Represents loss taken on write-down of property and equipment.~~

~~(h)~~f)

Represents the revaluation of ~~the Company’s~~TerrAscend’s contingent consideration liabilities.

~~(i)~~

~~Represents costs associated with executive severance and restructuring of business units.~~

~~(j)~~

~~Represents one-time legal settlement charges.~~

~~(k)~~g)

Includes one-time fees incurred in connection with ~~the Company’s~~TerrAscend’s acquisitions, such as expenses related to professional fees, consulting, legal, settlements, and accounting, that would otherwise not have been incurred. In addition, includes one-time charges for Sarbanes Oxley ~~implementation, as well as work completed in preparation~~Act of ~~becoming a US filer.~~2022 implementation. These fees are not indicative of ~~the Company’s~~TerrAscend’s ongoing costs.

~~(l)~~h)

Represents expenses associated with ERC transfer of assets with recourse.

Represents loss taken as a result on the derecognition of right of use assets.

Represents the (gain) loss on fair value of warrants, including effects of the foreign exchange of the USU.S. denominated preferred share warrants, as well as the revaluation of the fair value of the purchase option derivative asset.

~~(m)~~k)

Represents the reduction to the indemnification asset related to the Apothecarium tax audit settlement and statute expirations for tax years ended September 30, 2014 and September 30, 2015.

~~(n)~~l)

Represents impairment charges taken on TerrAscend's property and equipment, as well as write-downs of property and equipment.

Represents unrealized and realized ~~loss (gain)~~gain on fair value changes on strategic investments.

~~(o)~~n)

Represents the remeasurement of USD denominated cash and other assets recorded in C$ functional currency.

~~(p)~~

~~Represents accelerated depreciation taken in Maryland due to the move of the cultivation facility from Frederick and Hagerstown.~~

The ~~decrease~~increase in Adjusted EBITDA from continuing operations for the three and six months ended June 30, ~~2022~~2023 compared to the three and six months ended June 30, ~~2021~~2022 was primarily due to ~~lower volume and resulting gross margin compression~~implementation of adult use sales in ~~Pennsylvania related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania.~~New Jersey.

~~Pending and Subsequent Transactions~~

On April 8, 2022, the Company entered into a definitive agreement to acquire Allegany Medical Marijuana Dispensary ("AMMD"), a medical dispensary in Maryland from Moose Curve Holdings, LLC. Under the terms of the agreement, the Company will acquire 100% equity interest in AMMD for total consideration of $10,000 in cash, in addition to acquiring the real estate for $1,700. The transaction is subject to customary closing conditions and regulatory approvals. The Company intends to rebrand the 8,000 square foot dispensary as The Apothecarium.

On April 14, 2022, the Company entered into a definitive agreement to acquire KISA Enterprises MI, LLC and KISA Holdings, LLC ("Pinnacle"), a dispensary operator in Michigan, and related real estate, for total consideration of $28,500, payable in cash, two promissory notes in an aggregate amount of $10,000, and stock. The transaction includes six retail dispensary licenses, five of which are currently operational and located in the cities of Addison, Buchanana, Camden, Edmore, and Morenci, Michigan. The Company intends to rebrand each of the dispensaries under either the Gage or Cookies retail brand. This transaction is pending approval.

~~Changes in or Adoption of Accounting Principles~~

~~Information regarding the Company's adoption of new accounting and reporting standards is discussed in Note 2 to the accompanying condensed consolidated financial statements.~~

Descriptions of the recently issued and adopted accounting principles are included in Item 1. "Financial Statements" in Note 1, Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements.

Critical Accounting Policies and Estimates

The condensed consolidated financial statements have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements ~~require~~requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. The Company bases its estimates on historical experience and assumptions on an ongoing

basis. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and actual results, the Company's future financial statements will be affected.

There have been no significant changes to the critical accounting ~~policies and~~ estimates from the information provided in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operation," ~~included~~other than the significant judgment relating to variable interest entities.

Variable interest entities

Management has applied significant judgment on the decision to consolidate its variable interest entity (“VIE”), TerrAscend Growth Corp.. The Company consolidates VIE when it has a variable interest that provide it with (1) the power to direct the activities of a VIE that most significantly impact the VIE’s economic performance (power) and (2) the obligation to absorb losses of the VIE that potentially could be significant to the VIE or the right to receive benefits from the VIE that potentially could be significant to the VIE (benefits). Key areas of judgment related to the assessment of the purpose and design of the VIE, the protection agreement in place, the ~~Annual Report on Form 10-K for~~board structure of TerrAscend Growth Corp., and substantive kick-out rights of the ~~year ended December 31, 2021, which was filed on March 17, 2022.~~Class A shareholders.

Emerging Growth Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, the condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

The Company will remain an emerging growth company until the earlier to occur of: (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of ~~the IPO,~~its initial public offering, (b) in which we have total annual gross revenue of ~~$1.07~~$1.235 billion or more, or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of our ~~common stock~~Common Stock that is held by non-affiliates exceeds ~~$700.0 million~~$700,000 as of the prior June 30th;30th; and (ii) the date on which the Company has issued more than ~~$1.0 billion~~$1,000,000 in non-convertible debt during the prior three-year period.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

There have been no material changes in the Company's primary risk exposures or management of market risks ~~for the quarter ended June 30, 2022~~ from those disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021.~~2022.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

~~The Company's~~Our management, with the participation of ~~its President~~our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of ~~the Company's~~our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, ~~the President~~our Chief Executive Officer and Chief Financial Officer concluded that, as of June 30, ~~2022 the Company's~~2023 our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by ~~the Company~~us in the reports that ~~it files~~we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to ~~the Company's~~our management, including ~~its President~~our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in ~~the Company's~~our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the ~~six months~~quarter ended June 30, ~~2022,~~2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

~~The Company~~

In the ordinary course of business, TerrAscend is ~~from time to time~~ involved in ~~various legal proceedings,~~a number of lawsuits incidental to its business, including litigation related to intellectual property, ~~product liability,~~ employment, and commercial matters. ~~TerrAscend~~Although it is difficult to predict the ultimate outcome of these cases, management believes that ~~none of the litigation in which it is currently involved in individually or in the aggregate, is~~any ultimate liability would not have a material ~~to the Company’s~~adverse effect on TerrAscend's consolidated ~~financial condition~~balance sheets or results of operations. ~~There~~At June 30, 2023, there were no pending lawsuits that could reasonably be expected to have ~~been no~~a material ~~changes to~~effect on the ~~Company's legal proceedings as previously disclosed in its Quarterly Report on Form 10-Q for the period ended March 31, 2022.~~results of TerrAscend's consolidated financial statements.

Item 1A. Risk Factors.

Investing in ~~the Company's~~our common ~~stock~~shares involves a high degree of risk. ~~For a detailed discussion of the risks that affect the Company's business, please refer~~In addition to the ~~section titled~~other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors described in Part I, Item 1.A. “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022. There have been no material changes to the Company's risk factors as previously disclosed in itsour Annual ~~Report on Form 10-K for~~Report. We may disclose changes to risk factors or disclose additional factors from time to time in our future filings with the ~~year ended December 31, 2021.~~SEC. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may impair our business operations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

The following information describes securities sold by the Company during the fiscal quarter ending June 30, 2022, which were not registered under the Securities Act. Included are securities issued in exchange other securities. The Company sold all of the securities listed below pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act, or Regulation D or Regulation S promulgated thereunder.None.

~~Recent Sales of Unregistered~~

Item 3. Defaults Upon Senior Securities

During the year ended December 31, 2021, the Company did not issue or sell any unregistered securities as previously disclosed in its Current Report on Form 8-K, as originally filed with the SEC on March 14, 2022.

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits.

Exhibit

Description of Exhibit Incorporated Herein by Reference
Filed
Number

Description

Form
File No.
Exhibit
Filing Date
Herewith

2.1*

Arrangement Agreement, dated October 8, 2018, by and among TerrAscend Corp., Canopy Growth Corporation, Canopy Rivers Corporation, JW Opportunities Master Fund, Ltd., JW Partners, LP and Pharmaceutical Opportunities Fund, LP.

10-12G
000-56363
2.1
11/2/2021

2.2*

Securities Purchase Agreement, dated February 10, 2019 by and among BTHHM Berkeley, LLC, PNB Noriega, LLC, V Products, LLC, certain limited liability company interest holders of each of the forgoing entities, Michael Thomsen and TerrAscend Corp. and WDB Holding CA, Inc.

10-12G
000-56363
2.2
11/2/2021

2.3*

Securities Purchase Agreement, dated February 10, 2019, by and among RHMT, LLC, Deep Thought, LLC, Howard Street Partners, LLC, certain limited liability company interest holders of each of the forgoing entities, Michael Thomsen, and TerrAscend Corp. and WDB Holding CA, Inc.

10-12G
000-56363
2.3
11/2/2021

2.4*

Securities Purchase and Exchange Agreement, dated August 1, 2019, by and among Ilera Holdings LLC, Mera I LLC, Mera II LLC, TerrAscend Corp., WDB Holding PA, Inc. and Osagie Imasogie.

10-12G
000-56363
2.4
11/2/2021

2.5*

Securities Purchase Agreement, dated February 10, 2019, by and among Gravitas Nevada Ltd, Verdant Nevada LLC, Green Achers Consulting Limited, TerrAscend Corp. and WDB Holding, NV, Inc.

10-12G
000-56363
2.5
11/2/2021

2.6*

Arrangement Agreement, dated August 31, 2021, by and between TerrAscend Corp. and Gage Growth Corp.

10-12G
000-56363
2.6
11/2/2021

2.7*

Membership Interest Purchase Agreement, dated August 31, 2021, by and between WDB Holdings MI, Inc. and 3 State Park, LLC, AEY Holdings, LLC, AEY Capital, LLC, AEY Thrive, LLC and Seller.

10-12G
000-56363
2.7
11/2/2021

2.8*

First Amendment to Membership Purchase Agreement, dated November 9, 2021, by and between WDB Holdings MI, Inc. and 3 State Park, LLC, AEY Holdings, LLC, AEY Capital, LLC, AEY Thrive, LLC and Seller.

10-12G/A
000-56363
2.8
12/22/2021

2.9

Amending Agreement, dated October 4, 2021, by and between TerrAscend Corp. and Gage Growth Corp.

10-12G
000-56363
2.9
11/2/2021

3.1

Articles of TerrAscend Corp., dated March 7, 2017

10-12G
000-56363
3.1
11/2/2021

3.2

Articles of Amendment to the Articles of TerrAscend Corp., dated November 30, 2018

10-12G/A
000-56363
3.2
12/22/2021


Exhibit		Description of Exhibit Incorporated Herein by Reference				Filed
Number	Description	Form	File No.	Exhibit	Filing Date	Herewith

3.1	Articles of TerrAscend Corp., dated March 7, 2017.	10-12G	000-56363	3.1	11/2/2021

3.2	Articles of Amendment to the Articles of TerrAscend Corp., dated November 30, 2018.	10-12G/A	000-56363	3.2	12/22/2021

3.3	Articles of Amendment to the Articles of TerrAscend Corp., dated May 22, 2020.	10-12G/A	000-56363	3.3	12/22/2021

3642

3.3

Articles of Amendment to the Articles of TerrAscend Corp., dated May 22, 2020.

10-12G/A
000-56363
3.3
12/22/2021

3.4

By-Laws of TerrAscend Corp., dated March 7, 2017

10-12G
000-56363
3.4
11/2/2021

10.1

Second Amendment to Membership Interest Purchase Agreement, dated March 8, 2022, by and between WDB Holdings MI, Inc. and 3 State Park, LLC, AEY Holdings, LLC, AEY Capital, LLC, AEY Thrive, LLC, Seller* and Gage Growth Corp.

8-K
000-56363
10.1
3/14/2022

10.2

Second Amendment to Arrangement Agreement, dated March 8, 2022, by and between TerrAscend Corp. and Gage Growth Corp.

8-K
000-56363
10.2
3/14/2022

10.3*

Debenture Agreement, dated March 10, 2020 by and between Canopy Growth and TerrAscend Canada, Inc.

10-K
000-56363
10.2
3/17/2022

10.4

Credit Agreement, dated December 18, 2020, by and among WDB Holding PA, Inc., the lenders party thereto and Acquiom Agency Services LLC, as Administrative Agent.

10-K
000-56363
10.3
3/17/2022

110.5

Credit Agreement, dated November 2, 2021, by and among Gage Growth Corp. and its subsidiaries, as Borrowers, and Chicago Atlantic Admin, LLC, as Administrative Agent and Collateral Agent

10-K
000-56363
10.21
3/17/2022

10.6*

Employment Agreement, dated May 23, 2022, by and between TerrAscend Corp. and Lynn Gefen

X

10.7

First Amendment to Credit Agreement, dated December 18, 2020, by and among WDB Holding PA, Inc., the lenders party thereto and Acquiom Agency Services LLC, as Administrative Agent

X

31.1*

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X
31.2*

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

X
32.1*

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X
32.2*

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document



3.4	By-laws of TerrAscend Corp., dated March 7, 2017.	10-12G	000-56363	3.3	11/2/2021

4.1	Warrant Indenture.	8-K	000-56363	4.1	6/29/2023

10.1#	Subscription Agreement, dated April 20, 2023, by and between TerrAscend Growth Corp. and TerInvest LLC.	8-K/A	000-56363	10.1	4/26/2023

10.2#	Protection Agreement, dated April 20, 2023, by and between TerrAscend Growth Corp. and TerrAscend Corp.	8-K/A	000-56363	10.2	4/26/2023

10.3	Form of Subscription Agreement for Equity Offering.	8-K	000-56363	10.1	6/29/2023

10.4	Form of Subscription Agreement for Equity Offering with Registered Broker-Dealer.	8-K	000-56363	10.2	6/29/2023

10.5	Form of Subscription Agreement for Debenture Offering.	8-K	000-56363	10.3	6/29/2023

10.6	Form of Convertible Debenture.	8-K	000-56363	10.4	6/29/2023

10.7	Fifth Amendment to Credit Agreement, dated April 14, 2023 by and among WDB Holding PA, Inc., the lenders party thereto and Acquiom Agency Services LLC as Administrative Agent.					X

10.8	Sixth Amendment to Credit Agreement, dated June 22, 2023 by and among WDB Holding PA, Inc., the lenders party thereto and Acquiom Agency Services LLC as Administrative Agent.					X

10.9	Joinder, Third Amendment to Credit Agreement and Security Agreements and Consent, dated as of June 9, 2023, among WDB Holding MI, Inc., Gage Growth Corp., Gage Innovations Corp., Cookies Retail Canada Corp., other borrower and lender parties thereto, and Chicago Atlantic Admin, LLC, as administrative agent for the lenders and Chicago Atlantic, as collateral agent for the secured parties thereto.					X

10.10	First Amendment, dated April 17, 2023, by and among subsidiaries of TerrAscend Corp., TerrAscend NJ LLC, HMS Processing LLC, HMS Hagerstown, LLC, HMS Health, LLC, as Borrowers, and Pelorus Fund REIT, LLC, as Lender.					X

10.11	Second Amendment, dated June 22, 2023, by and among subsidiaries of TerrAscend Corp., TerrAscend NJ LLC, HMS Processing LLC, HMS Hagerstown, LLC, HMS Health, LLC, as Borrowers, and Pelorus Fund REIT, LLC, as Lender.					X

31.1	Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.					X

31.2	Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.					X

3743



32.1*	Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	X

32.2*	Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.	X

101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.	X

101.SCH	Inline XBRL Taxonomy Extension Schema Document	X

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document	X

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document	X

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document	X

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document	X

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)	X

* This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of TerrAscend Corp. under the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

# Certain ~~confidential information has been excluded from~~portions of this exhibit have been omitted because ~~it is~~they are both (i) not material and (ii) ~~would be competitively harmful if publicly disclosed.~~the type of information the Company treats as private or confidential.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	~~Company Name~~TerrAscend Corp.

Date: August ~~11, 2022~~10, 2023	By:	/s/ Ziad Ghanem
		Ziad Ghanem
		President and Chief ~~Operating~~Executive Officer (Principal Executive Officer)






Date: August 10, 2023	By:	/s/ Keith Stauffer
		Keith Stauffer
		Chief Financial Officer (Principal Financial Officer)


	June 30, 2022			December 31, 2021
Beginning of period	$	492			1,782
Provision for sales returns		255			1,125
Expected credit losses		859			357
Write-offs charged against provision		(431	)		(2,772	)
Foreign currency translation adjustments		(27	)		-
Total provision for sales returns and allowances	$	1,148			492


Balance at December 31, 2021	$	90,326
Acquisitions (see Note 4)		150,272
Balance at June 30, 2022	$	240,598


	Canopy Growth (formerly RIV Capital) Loan			Canopy Growth- Canada Inc Loan			Other Loans			Canopy Growth- Arise Loan		Ilera Term Loan			KCR Loan			Gage loans			Total
Balance at December 31, 2021	$	8,680		$	42,165		$	7,915		$	8,900	$	115,233		$	2,250		$	-		$	185,143
Addition on acquisition		—			—			—			—		—			—			60,605			60,605
Loan amendment fee		—			—			—			—		(1,200	)		—			—			(1,200	)
Interest accretion		665			2,739			319			702		8,542			74			2,819			15,860
Principal and interest paid		(624	)		(3,837	)		(2,586	)		—		(7,662	)		(2,324	)		(2,811	)		(19,844	)
Effects of movements in foreign exchange		(142	)		(691	)		(94	)		—		—			—			—			(927	)
Ending carrying amount at June 30, 2022	$	8,579		$	40,376		$	5,554		$	9,602	$	114,913		$	-		$	60,613		$	239,637
Less: current portion		(309	)		(1,170	)		(464	)		—		(42	)		—			(56,871	)		(58,856	)
Non-current loans payable	$	8,270		$	39,206		$	5,090		$	9,602	$	114,871		$	-		$	3,742		$	180,781


	June 30, 2022
2022	$	56,589
2023		9,187
2024		131,869
2025		—
2026		—
Thereafter		82,491
Total principal payments	$	280,136


	Number of Proportionate Share Warrants Outstanding		Number of Proportionate Share Warrants Exercisable		Weighted Average Exercise Price $		Weighted Average Remaining Life (years)
Outstanding, December 31, 2021		8,590,908		8,590,908	$	5.69		0.64
Exercised		—
Outstanding, June 30, 2022		8,590,908		8,590,908	$	5.60		0.15


	June 30, 2022			March 10, 2022
Common Stock Price of TerrAscend Corp.	$	2.28		$	5.70
Warrant exercise price	$	8.66		$	8.66
Annual volatility	62.88% - 63.73%			61.65% - 61.87%
Annual risk-free rate		2.9	%		1.8	%
Expected term (in years)		1.5			1.7


Balance at December 31, 2021	$	868
Revaluation of purchase option derivative asset		(818	)
Balance at June 30, 2022	$	50


	June 30, 2022			December 31, 2021
Term (in years)		0.8			1.3
Risk-free rate		2.5	%		0.4	%
EBITDA discount rate		15.5	%		15.0	%
EBITDA volatility		37.1	%		44.0	%


Discount rate sensitivity	KCR
Increase 100 basis points	$	1,175
Increase 50 basis points	$	1,195
Decrease 50 basis points	$	1,236
Decrease 100 basis points	$	1,258